var title_f14_50_15136="Evaluation of polyarthritis";
var content_f14_50_15136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Evaluation of polyarthritis or polyarthralgia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 408px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An initial approach to the patient with polyarticular joint symptoms.",
"    <div class=\"footnotes\">",
"     CCP: citrulline containing peptide; CBC: complete blood cell count; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; ANA: antinuclear antibodies.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American College of Rheumatology Ad Hoc Committee on Clinical Guidelines, Arthritis Rheum 1996; 39:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15136=[""].join("\n");
var outline_f14_50_15136=null;
var title_f14_50_15137="Skinning vulvectomy incision";
var content_f14_50_15137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skinning vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The incision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15137=[""].join("\n");
var outline_f14_50_15137=null;
var title_f14_50_15138="NEC prematurity";
var content_f14_50_15138=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Necrotizing enterocolitis: Susceptibility of premature infants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immaturity of the intestinal epithelial barrier and the neonatal mucosal immune system predispose the premature infant to microbial invasion, which triggers the sequence of events leading to necrotizing enterocolitis (NEC). Stimulation of pro-inflammatory cytokines compromises intestinal defenses. An imbalance between epithelial cell injury and repair leads to cycle of bacterial invasion, immune activation, uncontrolled inflammation, and gut barrier failure.",
"    <div class=\"footnotes\">",
"     NO: nitric oxide; TNF-&alpha;: tumor necrosis factor - alpha.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hunter CJ, Upperman JS, Ford HR, Camerini V. Understanding the susceptibility of the premature infant to necrotizing entercolitis (NEC). Pediatr Res 2008; 63:117. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15138=[""].join("\n");
var outline_f14_50_15138=null;
var title_f14_50_15139="Tubal bands";
var content_f14_50_15139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Fallopian tube bands for sterilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The two rings or bands slide over a knuckle of fallopian tube using an introducer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15139=[""].join("\n");
var outline_f14_50_15139=null;
var title_f14_50_15140="Enteroatmospheric fistula";
var content_f14_50_15140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enteroatmospheric fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enteroatmospheric or exposed fistulas occur in the midst of an open abdomen with no overlying soft tissue. These fistulas occur when the abdomen is left open after trauma or emergency surgery. This photograph shows the appearance of superficial exposed fistulas draining atop the granulating wound of a frozen abdomen with an obliterated peritoneal cavity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15140=[""].join("\n");
var outline_f14_50_15140=null;
var title_f14_50_15141="Para-aminosalicylic acid: Drug information";
var content_f14_50_15141=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Para-aminosalicylic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/19/21812?source=see_link\">",
"    see \"Para-aminosalicylic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F133540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Paser&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F133569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitubercular Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F133543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Tuberculosis:",
"     </b>",
"     Oral: 8-12 g/day in 2-3 divided doses (",
"     <b>",
"      Note:",
"     </b>",
"     Studies have shown administration of 4 g twice daily is adequate to achieve the target serum concentration) (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F133558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Tuberculosis:",
"     </b>",
"     Oral: 200-300 mg/kg/day in 2-4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F133544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F133545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, the following adjustments have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aronoff, 2007:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% to 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Administer after hemodialysis: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous arteriovenous hemofiltration: Dose for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 4 g twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F133546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules, delayed release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paser&reg;: 4 g/packet (30s) [sugar free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F133523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with food. Do not use granules if packet is swollen or if granules are discolored (ie, brown or purple). Granules may be sprinkled on applesauce or yogurt (do not chew) or suspended in tomato or orange juice.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F133522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of tuberculosis used in combination with other antitubercular agents",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F133567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Pericarditis, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Encephalopathy, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin eruptions (including exfoliative dermatitis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Goiter (with or without myxedema), hypoglycemia, hypothyroidism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia (hemolytic), leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Eosinophilic pneumonia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F133526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aminosalicylic acid or any component of the formulation; severe renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F133510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Salicylate sensitivity: Patients with sensitivity to tartrazine dyes, nasal polyps, and asthma may have an increased risk of salicylate sensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric ulcer: Use with caution in patients with gastric ulcer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; contraindicated in patients with severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Salicylates may diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the anticoagulant effect of Salicylates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Salicylates may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Salicylates may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received  platelet inhibitors including aspirin (over 650 mg daily within 1 week). Monitor for bleeding and stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Salicylates may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Acid Phosphate: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: Salicylates may diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of other Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Salicylates may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F133528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been reported in animal reproduction studies. Salicylates have been noted to cross the placenta and enter fetal circulation. Aminosalicylic acid has been used safely during pregnancy; however, it should only be used if there are no alternatives for the treatment of multidrug-resistant tuberculosis (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F133549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14464802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following the administration of oral aminosalicylic acid 4 g to a lactating woman, peak maternal serum concentrations were 70.1 mcg/mL at 1 hour, peak milk concentrations were 1.1 mcg/mL at 3 hours, and the half-life of aminosalicylic acid in the breast milk was calculated to be 2.5 hours (Holdiness, 1984).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F133529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Paser Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g (30): $112.13",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14464905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Liver function at baseline; thyroid function (at baseline and every 3 months with prolonged therapy [&gt;3 months]) (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apir Pas (ES);",
"     </li>",
"     <li>",
"      Ca-Oripas (FI);",
"     </li>",
"     <li>",
"      Entepas (IE);",
"     </li>",
"     <li>",
"      Eupasal Sodico (IT);",
"     </li>",
"     <li>",
"      Italpas Sodico (IT);",
"     </li>",
"     <li>",
"      Mesacol (IN);",
"     </li>",
"     <li>",
"      Paramisan Sodium (GB);",
"     </li>",
"     <li>",
"      Parispas (ES);",
"     </li>",
"     <li>",
"      PAS (TR);",
"     </li>",
"     <li>",
"      Pas-Dexter (ES);",
"     </li>",
"     <li>",
"      Pas-Fatol N (DE);",
"     </li>",
"     <li>",
"      PAS-Infusion Bichsel (CH);",
"     </li>",
"     <li>",
"      Pasalba (AU);",
"     </li>",
"     <li>",
"      Quadrasa (FR, IT);",
"     </li>",
"     <li>",
"      Salf-Pas (IT);",
"     </li>",
"     <li>",
"      Vacopas (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F133509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aminosalicylic acid (PAS) is a highly-specific bacteriostatic agent active against",
"     <i>",
"      M. tuberculosis",
"     </i>",
"     . Structurally related to para-aminobenzoic acid (PABA) and its mechanism of action is thought to be similar to the sulfonamides, a competitive antagonism with PABA; disrupts plate biosynthesis in sensitive organisms.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F133525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily, &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 50% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (&gt;50%) via acetylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Reduced with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&gt;80% as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,&rdquo; 2003,",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 52(RR-11):3-5. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15141/abstract-text/12836625/pubmed\" id=\"12836625\" target=\"_blank\">",
"        12836625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Tuberculosis,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1993, 35(908):99-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15141/abstract-text/8412982/pubmed\" id=\"8412982\" target=\"_blank\">",
"        8412982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holdiness MR, \"Antituberculosis Drugs and Breast-Feeding,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1984, 144(9):1888.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15141/abstract-text/6548112/pubmed\" id=\"6548112\" target=\"_blank\">",
"        6548112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10341 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-AF7A4312D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15141=[""].join("\n");
var outline_f14_50_15141=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133540\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133569\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133543\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133558\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133544\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133545\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133546\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133520\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133506\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133523\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133522\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133567\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133526\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133510\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298737\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133515\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133517\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133528\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133549\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14464802\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133529\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322983\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14464905\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539813\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133509\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133525\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10341\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10341|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/19/21812?source=related_link\">",
"      Para-aminosalicylic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_50_15142="Propylthiouracil: Pediatric drug information";
var content_f14_50_15142=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Propylthiouracil: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"    see \"Propylthiouracil: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/31/30196?source=see_link\">",
"    see \"Propylthiouracil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10163904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Propyl-Thyracil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antithyroid Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (adjust dosage to maintain T",
"     <sub>",
"      3",
"     </sub>",
"     , T",
"     <sub>",
"      4",
"     </sub>",
"     , and TSH in normal range; elevated T",
"     <sub>",
"      3",
"     </sub>",
"     may be sole indicator of inadequate treatment. Elevated TSH indicates excessive antithyroid treatment): Initial: 5 mg/kg/day in divided doses every 8 hours; if no response in 36-48 hours, increase dose by 50%; usual range: 5-10 mg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"      see \"Propylthiouracil: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Adjust dosage to maintain T",
"     <sub>",
"      3",
"     </sub>",
"     , T",
"     <sub>",
"      4",
"     </sub>",
"     , and TSH in normal range; elevated T",
"     <sub>",
"      3",
"     </sub>",
"     may be sole indicator of inadequate treatment. Elevated TSH indicates excessive antithyroid treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 5-7 mg/kg/day in divided doses every 8 hours",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-10 years: 50-150 mg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;10 years: 150-300 mg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: Determined by patient response or",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     to",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of the initial dose in divided doses every 8-12 hours; this begins usually after 2 months on an effective initial dosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 300 mg/day in divided doses every 8 hours. In patients with severe hyperthyroidism, very large goiters, or both, the initial dosage may be increased to 400 mg/day; an occasional patient will require 600-900 mg/day; usual maintenance: 100-150 mg/day in divided doses every 8 hours (Goldberg, 2003; Nayak, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adjustment is not necessary",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10162707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM208533.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM208533.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer same time in relation to meals each day, either always with meals or always between meals",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in patients intolerant of methimazole to ameliorate hyperthyroidism symptoms in preparation for surgical treatment or radioactive iodine therapy (FDA approved in adults); treatment of hyperthyroidism in patients intolerant of methimazole and not candidates for surgical/radiotherapy (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F215107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Propylthiouracil may be confused with Purinethol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PTU is an error-prone abbreviation (mistaken as mercaptopurine [Purinethol&reg;;  6-MP])",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F215105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Periarteritis, vasculitis (ANCA-positive, cutaneous, leukocytoclastic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, drug fever, fever, headache, neuritis, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema nodosum, exfoliative dermatitis, pruritus, skin pigmentation, skin rash, skin ulcers, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Goiter, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, loss of taste, nausea, sialoadenopathy, splenomegaly, stomach pain, taste perversion, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, bleeding, granulopenia, hypoprothrombinemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Acute liver failure, cholestatic jaundice, hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, glomerulonephritis, nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Alveolar hemorrhage, interstitial pneumonitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Lymphadenopathy, SLE-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to propylthiouracil or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause hypoprothrombinemia and bleeding; monitor PT/INR. Use with caution in patients receiving other drugs known to cause myelosuppression, particularly agranulocytosis. Use should be limited to patients unable to tolerate methimazole or in whom surgery or radioactive iodine treatment are not appropriate.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause significant bone marrow depression; the most severe manifestation is agranulocytosis; aplastic anemia, thrombocytopenia, and leukopenia may also occur. Discontinue in the presence of unexplained fever. Has been associated with a variety of autoimmune reactions, including a lupus-like syndrome, as well as vasculitis; discontinuation may be warranted. Severe liver injury (some fatal) and acute liver failure (some cases requiring transplantation) have been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Patients should be counseled to recognize and report symptoms suggestive of hepatic dysfunction (especially in first 6 months of treatment); symptoms suggestive of hepatic dysfunction should prompt immediate discontinuation. Routine liver function test monitoring may not reduce risk due to unpredictable and rapid onset. Has been associated with rare but severe dermatologic reactions; discontinue in the presence of exfoliative dermatitis. Glomerulonephritis and interstitial nephritis with acute renal failure have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5722563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Propylthiouracil serum concentrations may be altered if taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F215043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F215058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Propylthiouracil has been found to readily cross the placenta. Teratogenic effects have not been observed; however, nonteratogenic adverse effects, including fetal and neonatal hypothyroidism, goiter, and hyperthyroidism, have been reported following maternal propylthiouracil use. The transfer of thyroid-stimulating immunoglobulins can stimulate the fetal thyroid",
"     <i>",
"      in utero",
"     </i>",
"     and transiently after delivery and may increase the risk of fetal or neonatal hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Uncontrolled maternal hyperthyroidism may result in adverse neonatal outcomes (eg, prematurity, low birth weight) and adverse maternal outcomes (eg, pre-eclampsia, congestive heart failure, stillbirth, and abortion). To prevent adverse fetal and maternal events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Antithyroid treatment is recommended for the control of hyperthyroidism during pregnancy. Propylthiouracil is considered first-line therapy, especially during the first trimester. Due to an increased risk of liver toxicity, use of methimazole may be preferred during the second and third trimesters. If drug therapy is changed, maternal thyroid function should be monitored after 2 weeks and then every 2-4 weeks. Propylthiouracil, along with other medications, is used for the treatment of thyroid storm in pregnant women; alternative therapy is recommended if oral administration is not possible.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The pharmacokinetics of propylthiouracil are not significantly changed during pregnancy; however, the severity of hyperthyroidism may fluctuate throughout pregnancy. Doses of propylthiouracil may be decreased as pregnancy progresses and discontinued weeks to months prior to delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, liver function tests, platelets, thyroid function tests (TSH, T",
"     <sub>",
"      3",
"     </sub>",
"     , T",
"     <sub>",
"      4",
"     </sub>",
"     ), prothrombin time, INR",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1061544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <table border=\"1\" frame=\"void\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Thyroid Function Tests",
"     </caption>",
"     <col align=\"left\" width=\"80\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         T",
"         <sub>",
"          4",
"         </sub>",
"         (thyroxine)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-7 d",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         10.1-20.9 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-14 d",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         9.8-16.6 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 mo to 1 y",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         5.5-16.0 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;1 y",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         4.0-12.0 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         FTI",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-3 d",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         9.3-26.6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-4 wk",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         7.6-20.8",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-4 mo",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         7.4-17.9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-12 mo",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         5.1-14.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-6 y",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         5.7-13.3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;6 y",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         4.8-14.0",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         T",
"         <sub>",
"          3",
"         </sub>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Newborns",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         100-470 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-5 y",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         100-260 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-10 y",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         90-240 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 y to Adult",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         70-210 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         T",
"         <sub>",
"          3",
"         </sub>",
"         uptake",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         35%-45%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"left\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         TSH",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Cord",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         3-22 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-3 d",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;40 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-7 d",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;25 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;7 d",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         0-10 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits the synthesis of thyroid hormones by blocking the oxidation of iodine in the thyroid gland; blocks synthesis of thyroxine and triiodothyronine",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For significant therapeutic effects 24-36 hours are required; remission of hyperthyroidism usually does not occur before 4 months of continued therapy",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 75% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 80% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 1.5-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     End-stage renal disease: 8.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 1 hour; persists for 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 35% excreted in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/31/30196?source=see_link\">",
"      see \"Propylthiouracil: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not exceed prescribed dosage; take at regular intervals around-the-clock; notify physician or pharmacist if fever, sore throat, unusual bleeding or bruising, headache, nausea, vomiting, loss of appetite, itchiness, dark-colored urine, yellowing of your skin or eyes, tiredness, or general malaise occurs; be aware that severe liver injury has occurred in patients taking propylthiouracil",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F215052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 5 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Ora-Plus&reg; and Ora-Sweet&reg;. Crush twenty 50 mg propylthiouracil tablets in a mortar and reduce to a fine powder. Add small portions of vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label \"shake well\" and \"refrigerate\". Stable for 91 days refrigerated (preferred) and 70 days at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin, Clinical Management Guidelines for Obstetrician-Gynecologists, Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001), &ldquo;Thyroid Disease in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2002, 100(2):387-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15142/abstract-text/12166417/pubmed\" id=\"12166417\" target=\"_blank\">",
"        12166417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark SM, Saade GR, Snodgrass WR, et al, &ldquo;Pharmacokinetics and Pharmacotherapy of Thionamides in Pregnancy,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2006, 28(4):477-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15142/abstract-text/16885714/pubmed\" id=\"16885714\" target=\"_blank\">",
"        16885714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper DS, \"Antithyroid Drugs,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(9):905-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15142/abstract-text/15745981/pubmed\" id=\"15745981\" target=\"_blank\">",
"        15745981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diav-Citrin O and Ornoy A, &ldquo;Teratogen Update: Antithyroid Drugs &minus; Methimazole, Carbimazole, and Propylthiouracil,&rdquo;",
"      <i>",
"       Teratology",
"      </i>",
"      , 2002, 65(1):38-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15142/abstract-text/11835230/pubmed\" id=\"11835230\" target=\"_blank\">",
"        11835230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldberg PA and Inzucchi SE, \"Critical Issues in Endocrinology,\"",
"      <i>",
"       Clin Chest Med",
"      </i>",
"      , 2003, 24(4):583-606.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15142/abstract-text/14710692/pubmed\" id=\"14710692\" target=\"_blank\">",
"        14710692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee A, Moretti, ME, Collantes A, et al, &ldquo;Choice of Breastfeeding and Physicians' Advice: A Cohort Study of Women Receiving Propylthiouracil,",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 106(1 Pt 1):27-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15142/abstract-text/10878145/pubmed\" id=\"10878145\" target=\"_blank\">",
"        10878145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lock DR and Sthoeger ZM, &ldquo;Severe Hepatotoxicity on Beginning Propylthiouracil Therapy,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 1997, 24(4):267-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15142/abstract-text/9252857/pubmed\" id=\"9252857\" target=\"_blank\">",
"        9252857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandel SJ and Cooper DS, &ldquo;The Use of Antithyroid Drugs in Pregnancy and Lactation,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2001, 86(6):2354-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15142/abstract-text/11397822/pubmed\" id=\"11397822\" target=\"_blank\">",
"        11397822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nayak B and Burman K, &ldquo;Thyrotoxicosis and Thyroid Storm,&rdquo;",
"      <i>",
"       Endocrinol Metab Clin North Am",
"      </i>",
"      , 2006, 35(4):663-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15142/abstract-text/17127140/pubmed\" id=\"17127140\" target=\"_blank\">",
"        17127140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raby C, Lagorce JF, Jambut-Absil AC, et al, &ldquo;The Mechanism of Action of Synthetic Antithyroid Drugs: Iodine Complexation During Oxidation of Iodide,&rdquo;",
"      <i>",
"       Endocrinology",
"      </i>",
"      , 1990, 126(3):1683-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15142/abstract-text/1689656/pubmed\" id=\"1689656\" target=\"_blank\">",
"        1689656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12745 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15142=[""].join("\n");
var outline_f14_50_15142=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10163904\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215073\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061542\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444885\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061536\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215047\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215033\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10162707\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061546\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061545\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215107\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215105\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061551\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061535\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061534\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299953\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215042\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722563\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215043\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215058\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061541\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061544\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061533\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061549\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061550\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061540\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215052\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12745\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12745|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=related_link\">",
"      Propylthiouracil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/31/30196?source=related_link\">",
"      Propylthiouracil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_50_15143="Sacral neuromodulation PI";
var content_f14_50_15143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sacral neuromodulation device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Illustrated depiction of device placement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Medtronic, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15143=[""].join("\n");
var outline_f14_50_15143=null;
var title_f14_50_15144="Pathophysiology and clinical presentation of ischemic chest pain";
var content_f14_50_15144=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and clinical presentation of ischemic chest pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/50/15144/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/50/15144/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/50/15144/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/50/15144/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/50/15144/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/50/15144/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/50/15144/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with chest pain often undergo a thorough evaluation to assess the possible presence of anginal pain due to myocardial ischemia, which is the result of coronary artery disease or left ventricular hypertrophy. A careful history and physical examination is critical to accurately establish the diagnosis of angina pectoris and to exclude other causes of chest pain, such as musculoskeletal problems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A clinical diagnosis of angina pectoris has a 90 percent predictive accuracy for the presence of myocardial ischemia, which is most often the result of coronary disease. However, based upon Bayesian principles, the predictive accuracy varies with the prevalence of coronary disease in the population (eg, men versus women, young versus old) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The predictive accuracy of angina is equal to or perhaps greater than the diagnostic accuracy of exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology and clinical manifestations of ischemic chest pain will be reviewed here. The evaluation of the patient with suspected ischemic chest pain is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ANGINA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms responsible for the sensation of angina are complex and not clearly defined. An important feature is that ischemia reduces the formation of adenosine triphosphate (ATP), resulting in the development of acidosis, the loss of the normal ATP sodium-potassium pump, the loss of myocardial membrane integrity, and the release of chemical substances that stimulate chemosensitive and mechanoreceptive receptors innervated by unmyelinated nerve cells found within cardiac muscle fibers and around the coronary vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/5\">",
"     5",
"    </a>",
"    ]. The substances that are released include lactate, serotonin, bradykinin, histamine, reactive oxygen species, and adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In addition, there are substances released from platelets, which often spontaneously aggregate in the area of a coronary artery stenosis, which may also be responsible for myocardial ischemia and angina. These include serotonin, thromboxane A2, and 5-hydroxytyrptamine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is substantial evidence that the primary mediator of angina is adenosine, via stimulation of the A1 adenosine receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. It is also possible that venodilation as a response to ischemia can activate these receptors. The nerve fibers travel along the sympathetic afferent pathways from the heart and enter the sympathetic ganglia in lower cervical and upper thoracic spinal cord (C7-T4). Impulses are then transmitted via the ascending spinothoracic pathways to the medial and lateral thalamus and ultimately activate several areas of the cerebral cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angina is a discomfort that is referred to the corresponding dermatomes that supply sympathetic afferent nerves to the same segments of the spinal cord as the heart (ie, C7-T4) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/5\">",
"     5",
"    </a>",
"    ]. Furthermore, stimulation of sensory receptors in different myocardial regions results in the transmission via the same neural pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These characteristics account for two typical features of angina: It is often a diffuse discomfort felt in the chest, neck, lower jaw, and down the arm; and most patients experience angina in the same distribution, regardless of which area of the myocardium is ischemic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF ANGINA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angina is caused by myocardial ischemia, which occurs whenever myocardial oxygen demand exceeds oxygen supply. An understanding of the pathophysiology of angina first requires a brief review of the determinants of oxygen demand and supply (",
"    <a class=\"graphic graphic_table graphicRef53315 \" href=\"UTD.htm?0/47/765\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Myocardial oxygen demand",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four major factors that determine myocardial work and therefore myocardial oxygen demand:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heart rate",
"     </li>",
"     <li>",
"      Systolic blood pressure (the clinical marker of afterload)",
"     </li>",
"     <li>",
"      Myocardial wall tension or stress (the product of ventricular end-diastolic volume or preload and myocardial muscle mass)",
"     </li>",
"     <li>",
"      Myocardial contractility",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical conditions associated with an increase in oxygen demand must affect one or more of these parameters. Examples include increased catecholamines or sympathetic tone, as with vigorous exertion or mental stress [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/15\">",
"     15",
"    </a>",
"    ], tachycardia of any etiology, hypertension, cold, and left ventricular hypertrophy.",
"   </p>",
"   <p>",
"    Myocardial contractility and wall stress cannot be measured clinically. As a result, myocardial oxygen demands are estimated clinically by the multiplication product (also called the",
"    <strong>",
"     double product",
"    </strong>",
"    ) of the heart rate and the systolic blood pressure. Individuals reproducibly experience angina during exercise testing when functional capacity exceeds a well-defined",
"    <strong>",
"     angina",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     threshold",
"    </strong>",
"    or absolute double product value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Myocardial oxygen supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major determinants of oxygen supply are the oxygen carrying capacity of the blood, which is affected by a variety of factors including oxygen tension and the hemoglobin concentration; the degree of oxygen unloading from hemoglobin to the tissues, which is related to 2,3 diphosphoglycerate levels; and the coronary artery blood flow.",
"   </p>",
"   <p>",
"    Coronary blood flow is influenced by the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary artery diameter and tone (resistance) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Collateral blood flow.",
"     </li>",
"     <li>",
"      Perfusion pressure, which is determined by the pressure gradients from the aorta to the coronary artery and, since flow is from epicardium to endocardium, from the coronary artery to the endocardial capillaries. The flow within the endocardium is determined by the left ventricular end-diastolic pressure.",
"     </li>",
"     <li>",
"      Heart rate, which affects the duration of diastole; importantly, coronary artery flow primarily occurs during diastole.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any clinical setting that reduces myocardial oxygen supply can cause ischemia and angina. The most frequent cause is coronary atherosclerosis, but other etiologies include coronary artery vasospasm, fibrosis, embolism, dissection, and arteritis. In addition, stimulation of the esophagus by acid can cause coronary artery vasoconstriction and a reduction in coronary blood flow via a neural cardioesophageal reflex [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angina can also occur after eating. Postprandial angina results from a redistribution of blood flow, away from territories supplied by severely stenosed coronary arteries to those supplied by less diseased or normal arteries (ie, a steal phenomenon) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. This may be due to sympathetic activation from food ingestion, with norepinephrine-induced vasoconstriction in diseased vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should be directed at the characteristics of the discomfort, other symptoms that can occur, and provoking factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Characteristics of the chest discomfort",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with angina often has a fairly typical history (",
"    <a class=\"graphic graphic_table graphicRef59572 \" href=\"UTD.htm?14/52/15179\">",
"     table 2",
"    </a>",
"    ). However, there is marked heterogeneity of the responses to stimuli that can produce ischemia such as exercise mental stress, exercise, and other factors of daily life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/21\">",
"     21",
"    </a>",
"    ]. Nevertheless, a number of features of the chest discomfort should be addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Quality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angina is usually characterized more as a discomfort rather than pain, and may be difficult to describe. Terms frequently used by patients include squeezing, tightness, pressure, constriction, strangling, burning, heart burn, fullness in the chest, band-like sensation, knot in the center of the chest, lump in throat, ache, heavy weight on chest (elephant sitting on chest), like a bra too tight, and toothache (when there is radiation to the lower jaw) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/24\">",
"     24",
"    </a>",
"    ]. In some cases, the patient cannot qualify the nature of the discomfort, but places his or her fist in the center of the chest, known as the \"Levine sign&rsquo;.",
"   </p>",
"   <p>",
"    It is generally not described as sharp, dull-aching, knife-like, stabbing, or pins and needles-like. In a report of patients presenting to the emergency department, \"sharp\" or \"stabbing\" pain was a low risk description, particularly when the pain was pleuritic or positional, was fully reproducible by palpation, and the patient had no history of angina or myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/25\">",
"     25",
"    </a>",
"    ]. No patient who presented with these findings had a cardiac etiology for the pain.",
"   </p>",
"   <p>",
"    The following additional characteristics are typically seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angina is typically gradual in onset and offset, with the intensity of the discomfort increasing and decreasing over several minutes. In contrast, noncardiac pain is often of greatest intensity at its onset and often has an abrupt onset and offset.",
"     </li>",
"     <li>",
"      Since angina is a referred discomfort, patients tend to have the same quality of chest discomfort with recurrent ischemic episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/14\">",
"       14",
"      </a>",
"      ]. The discomfort is generally the same prior to or with a myocardial infarction and is the same as prior to revascularization by either surgery or percutaneous coronary intervention.",
"     </li>",
"     <li>",
"      Angina is a constant discomfort that does not change with respiration or position. It is also not provoked or worsened with palpation of the chest wall.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Location and radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, angina is a referred pain due to involvement of a neural reflex pathway via the thoracic and cervical nerves. As a result, it is not felt in a specific spot, but is usually a diffuse discomfort that may be difficult to localize.",
"   </p>",
"   <p>",
"    The patient often indicates the entire chest when asked where the discomfort is felt. Pain that localizes to one small area of the chest is more likely of chest wall or pleural origin rather than visceral.",
"   </p>",
"   <p>",
"    Angina is referred to the corresponding dermatomes (C7-T4) that supply afferent nerves to the same segments of the spinal cord as the heart. Thus, angina often radiates to other parts of the body including the upper abdomen (epigastric), shoulders, arms (upper and forearm), wrist, fingers, neck and throat, lower jaw and teeth (but not upper jaw), and rarely to the back (specifically the interscapular region) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/23,26\">",
"     23,26",
"    </a>",
"    ]. Radiation to both arms is a stronger predictor of acute myocardial infarction. The location and radiation of angina is usually the same each time. Occasionally, the location and radiation, but not quality, may be different after bypass surgery due to the disruption of the neural innervation of the heart.",
"   </p>",
"   <p>",
"    Isolated back pain is unusual in patients with angina. However, it may be seen with an aortic dissection that also involves the coronary arteries and is associated with myocardial ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Provoking factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angina is often elicited by activities and situations that increase myocardial oxygen demand, including physical activity, cold, emotional stress, sexual intercourse, meals, or lying down (which results in an increase in venous return and increase in wall stress) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. It has been strongly recommended that patients also be questioned about cocaine use [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In a study of 3946 patients with an acute myocardial infarction, 1 percent had used cocaine within the prior year; the risk of a myocardial infarction was increased 23.7 times over baseline in the 60 minutes after cocaine use [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\", section on 'Myocardial ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postprandial pain is generally considered to be gastrointestinal in origin. However, it may also be anginal, especially in patients with severe ischemia (eg, left main or three vessel coronary disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angina occurs more commonly in the morning due to a diurnal increase in sympathetic tone. Enhanced sympathetic activity raises heart rate, blood pressure, vessel tone and resistance (resulting in a reduced vessel diameter that causes any fixed lesion to be more occlusive), and platelet aggregability (resulting in the release or vasoactive substances, such as serotonin, thromboxane A2, and 5 hydroxytryptamine) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Duration and relief",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angina generally lasts for two to five minutes. It is not a fleeting discomfort, which lasts only for a few seconds or less than a minute, and it generally does not last for 20 to 30 minutes, unless the patient is experiencing an acute coronary syndrome, especially myocardial infarction.",
"   </p>",
"   <p>",
"    Factors that reduce oxygen demand or increase oxygen supply will result in relief of angina. These include cessation of activity, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (which is a venodilator, reducing venous return, and a coronary artery vasodilator that increases coronary blood flow), sitting up (which reduces venous return and preload), and maneuvers that increase vagal tone and, hence, slow heart rate and reduce venous return. These include Valsalva maneuver, and carotid sinus pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to appreciate that pain relief with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is not specific for angina, since a similar response may be seen with esophageal spasm or other gastrointestinal problems as nitroglycerin also relaxes smooth muscle. In a review of 459 patients presenting to an emergency department with chest pain, the percentage of patients with relief of chest pain with nitroglycerin was similar among those with and without active coronary disease (35 versus 41 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angina is often associated with other symptoms. The most common is shortness of breath, which may reflect mild pulmonary congestion, resulting from ischemia-mediated reduction in diastolic relaxation and the occurrence of diastolic dysfunction, elevated left ventricular end-diastolic, left atrial and pulmonary venous pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/26,36\">",
"     26,36",
"    </a>",
"    ]. Other symptoms may include belching, nausea, indigestion, diaphoresis, dizziness, lightheadedness, clamminess, and fatigue. However, these symptoms may be seen with other etiologies for chest pain, especially gastrointestinal causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is common for patients with diabetes mellitus, who often have autonomic (sympathetic) dysfunction, to experience \"silent ischemia\" or best termed &ldquo;discomfortless ischemia&rdquo;. In this situation, they may experience the above symptoms associated with ischemia in the absence of the chest discomfort due to failure of transmission of neural impulses from the heart to the spinal cord.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Noncardiac chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific chest pain characteristics can be used to help differentiate cardiac from noncardiac causes (",
"    <a class=\"graphic graphic_table graphicRef53227 graphicRef77753 \" href=\"UTD.htm?41/41/42653\">",
"     table 3A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In two systematic reviews, the following characteristics were found to be more typical of",
"    <strong>",
"     nonischemic",
"    </strong>",
"    chest discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pleuritic pain, sharp or knife-like pain related to respiratory movements or cough",
"     </li>",
"     <li>",
"      Primary or sole location in the mid or lower abdominal region",
"     </li>",
"     <li>",
"      Any discomfort localized with one finger",
"     </li>",
"     <li>",
"      Any discomfort reproduced by movement or palpation",
"     </li>",
"     <li>",
"      Constant pain lasting for days",
"     </li>",
"     <li>",
"      Fleeting pains lasting for a few seconds or less",
"     </li>",
"     <li>",
"      Pain radiating into the lower extremities or above the mandible",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some patients with ACS present with atypical types of chest pain. This was illustrated in the Multicenter Chest Pain Study in which acute ischemia was diagnosed in 22 percent of patients who presented with sharp or stabbing pain and 13 percent who presented with pleuritic-type pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, some patients who appear to have a noncardiac cause of chest pain have other serious conditions including acute aortic dissection, pulmonary embolism, tension pneumothorax, myocarditis, perforating peptic ulcer, and esophageal rupture (",
"    <a class=\"graphic graphic_table graphicRef53227 graphicRef77753 \" href=\"UTD.htm?41/41/42653\">",
"     table 3A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/39\">",
"     39",
"    </a>",
"    ]. It is essential to consider these alternate diagnoses to avoid potentially dangerous errors in management, such as the administration of thrombolytic therapy to a patient with an aortic dissection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemia can produce an impairment in myocardial function, which may result in the following findings on physical examination. All disappear with resolution of the ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Increase in heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemia can raise the heart rate even if the patient is receiving a beta blocker or calcium channel blocker. The increase in heart rate is induced by reflex sympathetic nervous system activation as a response to ischemia. It is not due to sympathetic activation due to anxiety, worry, or fear. Stimulation of a chemoreceptor located in the area of the proximal left anterior descending (LAD) artery results in activation of the sympathetic nervous system. This receptor binds vasoactive amines, in particular serotonin, which is found in high levels in platelets and is released during platelet aggregation. Platelets are known to spontaneously aggregate at the site of an atheroma, causing further obstruction to blood flow and, therefore, additional ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Elevation in blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemia often causes a hypertensive response. The elevation in blood pressure is induced by both sympathetic activation in response to ischemia and stimulation of the LAD chemoreceptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     New heart sounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemia-induced myocardial dysfunction can lead to changes in the normal heart sounds. The second heart sound may become paradoxically split due to delayed relaxation of the left ventricular myocardium and delayed closure of the aortic valve. There may also be a third or fourth heart sound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     New/changed murmurs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired myocardial function may result in a new mitral regurgitation murmur, which appears to be due to papillary muscle dysfunction causing apical tethering or tenting of the leaflets, or changes in the intensity or timing of pre-existing murmurs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Precordial pulsation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the chest wall may reveal abnormal pulsations that correlate with transient left ventricular dysfunction. An area of dyskinesis may develop, especially at the apex of the left ventricle or at the anterior axillary line (location of the left ventricular wall), reflecting disease of the LAD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"     \"Examination of the precordial pulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Palpation of the left anterior chest wall at the anterior axillary line may reveal an abnormal tapping in systole, which reflects the presence of an area of dyskinetic contraction or aneurysm. Transient right ventricular dysfunction may lead to a transient right ventricular heave or sternal pulsation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263112215\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the following recommendation, which addresses the clinical evaluation in the initial diagnosis of stable ischemic heart disease, made in the 2012",
"    <span class=\"nowrap\">",
"     ACCF/AHA/ACP/AATS/PCNA/SCAI/STS",
"    </span>",
"    guideline for the diagnosis and management of patients with stable ischemic heart disease: &ldquo;Patients with chest pain should receive a thorough history and physical examination to assess the probability of ischemic heart disease before additional testing&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15144/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=see_link\">",
"       \"Patient information: Chest pain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=see_link\">",
"       \"Patient information: Chest pain (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H287538006\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mechanisms responsible for the sensation of ischemic chest pain (angina) are complex and not clearly defined. There is substantial evidence that the primary mediator of angina is adenosine. Myocardial ischemia occurs whenever myocardial oxygen demand exceeds oxygen supply.",
"     </li>",
"     <li>",
"      The patient with angina often has a fairly typical history (",
"      <a class=\"graphic graphic_table graphicRef59572 \" href=\"UTD.htm?14/52/15179\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Angina is usually characterized more as a discomfort (pressure, squeezing, constriction, choking, burning, tightness, knot in throat or chest) rather than pain (sharp, stabbing, pins and needles-like.",
"     </li>",
"     <li>",
"      Angina is typically gradual in onset and offset. Once present, it is constant and does not change with position or respiration.",
"     </li>",
"     <li>",
"      Angina is not felt in a specific spot, but is usually a diffuse discomfort that may be difficult to localize.",
"     </li>",
"     <li>",
"      Angina is usually elicited by activities and situations that increase myocardial oxygen demand.",
"     </li>",
"     <li>",
"      Angina generally lasts for two to five minutes.",
"     </li>",
"     <li>",
"      Angina is often associated with other symptoms; the most common are shortness of breath, nausea, diaphoresis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myocardial ischemia may be accompanied by no abnormal findings on examination or the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tachycardia",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      New and potentially abnormal heart sounds and murmurs or changes in a pre-existing murmur.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/1\">",
"      Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979; 300:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/2\">",
"      Cohn PF, Harris P, Barry WH, et al. Prognostic importance of anginal symptoms in angiographically defined coronary artery disease. Am J Cardiol 1981; 47:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/3\">",
"      Goldman L, Cook EF, Mitchell N, et al. Incremental value of the exercise test for diagnosing the presence or absence of coronary artery disease. Circulation 1982; 66:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/4\">",
"      Wilson RF, Marcus ML, Christensen BV, et al. Accuracy of exercise electrocardiography in detecting physiologically significant coronary arterial lesions. Circulation 1991; 83:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/5\">",
"      Foreman RD. Mechanisms of cardiac pain. Annu Rev Physiol 1999; 61:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/6\">",
"      Benson CJ, Eckert SP, McCleskey EW. Acid-evoked currents in cardiac sensory neurons: A possible mediator of myocardial ischemic sensation. Circ Res 1999; 84:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/7\">",
"      Longhurst JC, Tjen-A-Looi SC, Fu LW. Cardiac sympathetic afferent activation provoked by myocardial ischemia and reperfusion. Mechanisms and reflexes. Ann N Y Acad Sci 2001; 940:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/8\">",
"      Fu LW, Longhurst JC. Interactions between histamine and bradykinin in stimulation of ischaemically sensitive cardiac afferents in felines. J Physiol 2005; 565:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/9\">",
"      Fu LW, Longhurst JC. Activated platelets contribute to stimulation of cardiac afferents during ischaemia in cats: role of 5-HT(3) receptors. J Physiol 2002; 544:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/10\">",
"      Fu LW, Guo ZL, Longhurst JC. Undiscovered role of endogenous thromboxane A2 in activation of cardiac sympathetic afferents during ischaemia. J Physiol 2008; 586:3287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/11\">",
"      Sylv&eacute;n C, Beermann B, Jonzon B, Brandt R. Angina pectoris-like pain provoked by intravenous adenosine in healthy volunteers. Br Med J (Clin Res Ed) 1986; 293:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/12\">",
"      Lagerqvist B, Sylv&eacute;n C, Beermann B, et al. Intracoronary adenosine causes angina pectoris like pain--an inquiry into the nature of visceral pain. Cardiovasc Res 1990; 24:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/13\">",
"      Gaspardone A, Crea F, Tomai F, et al. Muscular and cardiac adenosine-induced pain is mediated by A1 receptors. J Am Coll Cardiol 1995; 25:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/14\">",
"      Crea F, Gaspardone A, Kaski JC, et al. Relation between stimulation site of cardiac afferent nerves by adenosine and distribution of cardiac pain: results of a study in patients with stable angina. J Am Coll Cardiol 1992; 20:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/15\">",
"      Goldberg AD, Becker LC, Bonsall R, et al. Ischemic, hemodynamic, and neurohormonal responses to mental and exercise stress. Experience from the Psychophysiological Investigations of Myocardial Ischemia Study (PIMI). Circulation 1996; 94:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/16\">",
"      Hillis LD, Braunwald E. Coronary-artery spasm. N Engl J Med 1978; 299:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/17\">",
"      Ganz P, Abben RP, Barry WH. Dynamic variations in resistance of coronary arterial narrowings in angina pectoris at rest. Am J Cardiol 1987; 59:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/18\">",
"      Chauhan A, Mullins PA, Taylor G, et al. Cardioesophageal reflex: a mechanism for \"linked angina\" in patients with angiographically proven coronary artery disease. J Am Coll Cardiol 1996; 27:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/19\">",
"      Baliga RR, Rosen SD, Camici PG, Kooner JS. Regional myocardial blood flow redistribution as a cause of postprandial angina pectoris. Circulation 1998; 97:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/20\">",
"      Chung WY, Sohn DW, Kim YJ, et al. Absence of postprandial surge in coronary blood flow distal to significant stenosis: a possible mechanism of postprandial angina. J Am Coll Cardiol 2002; 40:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/21\">",
"      Sheps DS, McMahon RP, Pepine CJ, et al. Heterogeneity among cardiac ischemic and anginal responses to exercise, mental stress, and daily life. Am J Cardiol 1998; 82:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/22\">",
"      Sampson JJ, Cheitlin MD. Pathophysiology and differential diagnosis of cardiac pain. Prog Cardiovasc Dis 1971; 13:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/23\">",
"      Constant J. The clinical diagnosis of nonanginal chest pain: the differentiation of angina from nonanginal chest pain by history. Clin Cardiol 1983; 6:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/24\">",
"      Kreiner M, Okeson JP, Michelis V, et al. Craniofacial pain as the sole symptom of cardiac ischemia: a prospective multicenter study. J Am Dent Assoc 2007; 138:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/25\">",
"      Lee TH, Cook EF, Weisberg M, et al. Acute chest pain in the emergency room. Identification and examination of low-risk patients. Arch Intern Med 1985; 145:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/26\">",
"      Christie LG Jr, Conti CR. Systematic approach to evaluation of angina-like chest pain: pathophysiology and clinical testing with emphasis on objective documentation of myocardial ischemia. Am Heart J 1981; 102:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/27\">",
"      Juneau M, Johnstone M, Dempsey E, Waters DD. Exercise-induced myocardial ischemia in a cold environment. Effect of antianginal medications. Circulation 1989; 79:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/28\">",
"      Kearney MT, Charlesworth A, Cowley AJ, MacDonald IA. William Heberden revisited: postprandial angina-interval between food and exercise and meal composition are important determinants of time to onset of ischemia and maximal exercise tolerance. J Am Coll Cardiol 1997; 29:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/29\">",
"      Schiffer F, Hartley LH, Schulman CL, Abelmann WH. Evidence for emotionally-induced coronary arterial spasm in patients with angina pectoris. Br Heart J 1980; 44:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/30\">",
"      Clinical policy for the initial approach to adults presenting with a chief complaint of chest pain, with no history of trauma. American College of Emergency Physicians. Ann Emerg Med 1995; 25:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/31\">",
"      Hollander JE, Brooks DE, Valentine SM. Assessment of cocaine use in patients with chest pain syndromes. Arch Intern Med 1998; 158:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/32\">",
"      Mittleman MA, Mintzer D, Maclure M, et al. Triggering of myocardial infarction by cocaine. Circulation 1999; 99:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/33\">",
"      Horwitz LD, Herman MV, Gorlin R. Clinical response to nitroglycerin as a diagnostic test for coronary artery disease. Am J Cardiol 1972; 29:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/34\">",
"      LEVINE SA. Carotid sinus massage. A new diagnostic test for angina pectoris. JAMA 1962; 182:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/35\">",
"      Henrikson CA, Howell EE, Bush DE, et al. Chest pain relief by nitroglycerin does not predict active coronary artery disease. Ann Intern Med 2003; 139:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/36\">",
"      Cook DG, Shaper AG. Breathlessness, angina pectoris and coronary artery disease. Am J Cardiol 1989; 63:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/37\">",
"      Panju AA, Hemmelgarn BR, Guyatt GH, Simel DL. The rational clinical examination. Is this patient having a myocardial infarction? JAMA 1998; 280:1256.",
"     </a>",
"    </li>",
"    <li>",
"     Braunwald, E, Mark, DB, Jones, RH, et al. Unstable Angina: Diagnosis and Management. Clinical Practice Guideline Number 10 (amended) AHCPR Publication No. 94-0602, Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, US Department of Health and Human Services, Rockville, May 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/39\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/40\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15144/abstract/41\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1472 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15144=[""].join("\n");
var outline_f14_50_15144=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H287538006\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ANGINA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY OF ANGINA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Myocardial oxygen demand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Myocardial oxygen supply",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Characteristics of the chest discomfort",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Quality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Location and radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Provoking factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Duration and relief",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Noncardiac chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Increase in heart rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Elevation in blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      New heart sounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      New/changed murmurs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H263112215\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287538006\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1472\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1472|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/47/765\" title=\"table 1\">",
"      Conditions increasing ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/52/15179\" title=\"table 2\">",
"      Definitions angina CASS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/43/12989\" title=\"table 3A\">",
"      Other diagnoses chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/29/43483\" title=\"table 3B\">",
"      Characteristics of major noncardiac causes of chest pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=related_link\">",
"      Examination of the precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=related_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_50_15145="Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants";
var content_f14_50_15145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/50/15145/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/50/15145/contributors\">",
"     Joseph B Philips III, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/50/15145/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/50/15145/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/50/15145/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/50/15145/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/50/15145/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/50/15145/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10685779\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ductus arteriosus (DA) is an important vascular connection between the main pulmonary artery and the aorta (",
"    <a class=\"graphic graphic_figure graphicRef65828 \" href=\"UTD.htm?10/31/10739\">",
"     figure 1",
"    </a>",
"    ). During fetal life, the DA diverts blood from the pulmonary artery into the aorta, thereby bypassing the lungs. After birth, the DA undergoes active constriction and eventual obliteration. A patent ductus arteriosus (PDA) occurs when the ductus fails to completely close after delivery.",
"   </p>",
"   <p>",
"    PDA occurs commonly in premature infants, especially in those with respiratory distress syndrome. In very low birth weight (VLBW) infants (birth weight below 1500 g); the incidence of PDA is about 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology, clinical features, and diagnosis of PDA in premature infants are reviewed here. The management of PDA in premature infants as well as the diagnosis and treatment of PDA in older infants and children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1002?source=see_link\">",
"     \"Management of patent ductus arteriosus in premature infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=see_link\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685787\">",
"    <span class=\"h1\">",
"     FETAL AND TRANSITIONAL DUCTAL CIRCULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the fetus, constriction of the pulmonary arteries leads to high vascular resistance, whereas the fetal systemic vascular resistance is low as a large proportion of the systemic circulation (about 40 percent) flows into the placenta, which has a very low vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, the majority of the blood flow exiting from the right ventricle passes away from the pulmonary arteries in a right-to-left shunt across the DA into the descending aorta and on to the placenta (",
"    <a class=\"graphic graphic_figure graphicRef66765 \" href=\"UTD.htm?14/43/15032\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70458 \" href=\"UTD.htm?10/39/10864\">",
"     figure 3",
"    </a>",
"    ). In the fetus, because of the large right-to-left shunting of blood, the ductus is a large vessel with a diameter similar to that of the descending aorta (",
"    <a class=\"graphic graphic_figure graphicRef65828 \" href=\"UTD.htm?10/31/10739\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8502?source=see_link\">",
"     \"Physiologic transition from intrauterine to extrauterine life\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the onset of respiration after delivery, the lungs expand and the systemic oxygen saturation rises, resulting in pulmonary vasodilatation and a drop in pulmonary vascular resistance. At the same time, systemic resistance rises with placental removal. These factors lead to a sudden reversal of blood flow in the DA from right-to-left to left-to-right shunting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8502?source=see_link\">",
"     \"Physiologic transition from intrauterine to extrauterine life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685794\">",
"    <span class=\"h2\">",
"     Patency of the ductus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ductus in the fetus is kept widely patent by low arterial oxygen content [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/3\">",
"     3",
"    </a>",
"    ]. Ductal patency also is influenced by vasodilators, including prostaglandins and nitric oxide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685801\">",
"    <span class=\"h3\">",
"     Prostaglandin E2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies have demonstrated that prostaglandin E2 (PGE2) concentration is an important determinant of ductal patency in the fetus, as PGE2 concentrations are higher in the fetal lamb than in the mother. In newborn lambs with no respiratory distress, PGE2 concentrations fall to maternal levels within a few hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/4\">",
"     4",
"    </a>",
"    ]; in contrast, newborn lambs with respiratory distress have PGE2 levels that are greater than fetal levels. The extent of ductal patency correlates with PGE2 values.",
"   </p>",
"   <p>",
"    Glucocorticoids appear to change the sensitivity of the DA to PGE2. For example,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    given to preterm lambs facilitates ductal constriction, perhaps by decreasing the sensitivity of the ductus to the dilating action of PGE2 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/5\">",
"     5",
"    </a>",
"    ]. This may explain the reduced incidence of PDA in VLBW infants whose mothers received antenatal glucocorticoid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of prostaglandins in maintaining ductal patency provides the rationale for the use of inhibitors of prostaglandin synthesis (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) in the treatment of PDA. antenatal administration of indomethacin also can induce intrauterine ductal constriction. In two case series, fetal echocardiography detected ductal constriction in approximately one-half of the fetuses whose mothers received antenatal indomethacin treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In one of these reports, ductal constriction occurred in 70 percent of fetuses after 31 weeks gestation and reversed with discontinuation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'NSAIDs and aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685808\">",
"    <span class=\"h3\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide (NO) appears to mediate ductal dilation in the newborn when arterial oxygen tension is at relatively high levels, but not in the fetus when oxygen levels are lower. In isolated rings of ductus arteriosus from premature fetal lambs, low oxygen caused ductal relaxation that was not affected by inhibitors of cyclooxygenase or by NO synthase [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/9\">",
"     9",
"    </a>",
"    ]. However, higher oxygen tension resulted in ductal constriction that was further increased by inhibition of cyclooxygenase or NO synthase. The NO that is important in regulating ductal tone is synthesized by endothelial cells in the lumen and vasa vasorum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685815\">",
"    <span class=\"h2\">",
"     Ductal constriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;At birth, the rise in systemic oxygen tension with the onset of breathing results in active constriction of the ductus, although the mechanisms for this response are not known. In addition, circulating levels of the vasodilator PGE2are decreased after delivery because of both reduced production following removal of the placenta and increased pulmonary clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/4\">",
"     4",
"    </a>",
"    ]. The predominance of constricting agents results in ductal constriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\", section on 'Ductal constriction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685822\">",
"    <span class=\"h2\">",
"     Permanent closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial sustained constriction of the ductus is the first step in permanent anatomic closure. The closure is thought to begin at the pulmonary end of the ductus and proceed toward the aortic end [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complete anatomic closure may take up to several months. Following initial functional constriction, the proliferation and infolding of endothelial cells, and migration of undifferentiated smooth muscle cells result in the obliteration of the ductal lumen and conversion to the ligamentum arteriosum [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. These histologic changes depend upon the initial ductal constriction and the resultant hypoxia within the ductal wall. Hypoxia of the inner vessel wall causes loss of cells from the muscle media and production of vascular endothelial growth factor (VEGF). VEGF stimulates endothelial cell proliferation that leads to formation of mounds in the intima that occlude the lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gestational age has a major impact upon the rate of ductal closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685829\">",
"    <span class=\"h3\">",
"     Term infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;At term, constriction of the ductus results in functional hemodynamic closure in 50 percent of infants within 24 hours after birth, in 90 percent at 48 hours, and in virtually all patients after 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/16\">",
"     16",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685837\">",
"    <span class=\"h3\">",
"     Preterm infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ductal closure is delayed in preterm infants and the risk of PDA is inversely proportional to gestational age. Respiratory illness also is associated with PDA especially in infants less than 30 weeks gestation. The ductus is functionally closed by the fourth day in nearly all healthy infants greater than 30 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/17\">",
"     17",
"    </a>",
"    ]. However, in ill infants less than 30 weeks gestation, PDA persists on the fourth day in approximately 65 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Closure is less likely to occur in infants who have hyaline membrane disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who do not receive antenatal corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The higher incidence of PDA in preterm infants may be explained by the effect of prematurity on the regulators of ductal tone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/20\">",
"     20",
"    </a>",
"    ]. Oxygen has a less pronounced constrictor effect in very premature lamb fetuses compared to late preterm fetuses because of greater sensitivity to the dilating actions of PGE2 and NO [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/9,21\">",
"     9,21",
"    </a>",
"    ]. This was also shown in a baboon model that demonstrated hypoxia in the term but not preterm fetus resulted in cell death, VEGF expression, endothelial proliferation, and intimal mound formation resulting in functional ductal closure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/12\">",
"     12",
"    </a>",
"    ]. These findings may be due to the much thinner premature DA that is able to extract its oxygen needs from the blood flow within its lumen. Thus, there is not the same degree of hypoxia resulting in a loss of the hypoxic signal for cell death and VEGF-induced endothelial cell proliferation in the very preterm infant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685844\">",
"    <span class=\"h3\">",
"     Reopening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histological changes following constriction of the DA occur rapidly in term infants and prevent subsequent reopening. However, in premature infants, the ductus can reopen after closure that occurs either spontaneously or following",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]. In one study of 77 preterm infants who had complete clinical closure of a PDA after indomethacin treatment, a clinically significant PDA recurred in 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/23\">",
"     23",
"    </a>",
"    ]. The rate of reopening was related to decreasing gestational age, occurring more frequently in infants less than 27 weeks gestation than in those 27 to 33 weeks (37 versus 11 percent). The reopening of the DA may be due to the same effects of prematurity that blunt the ductal response to factors that promote initial constriction at the time of delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685851\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC EFFECTS AND CLINICAL IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The shunting of blood through a PDA in premature infants is essentially all left-to-right. As a result, there is excessive flow through the pulmonary circulation and hypoperfusion of the systemic circulation. Radionuclide studies demonstrate pulmonary blood flow can be up to three times greater than that of the systemic blood flood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/24\">",
"     24",
"    </a>",
"    ]. The physiologic consequences of this &ldquo;ductal steal&rdquo; depend upon the size of the shunt and the response of the heart, lungs, and other organs to the shunt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685858\">",
"    <span class=\"h2\">",
"     Pulmonary effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In fetal lamb studies,",
"    <strong>",
"    </strong>",
"    excessive blood flow through the PDA resulted in increased hydrostatic pressure and increased lung fluid filtration in the pulmonary microvasculature (measured as lymph flow), which led to deterioration of pulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/25\">",
"     25",
"    </a>",
"    ]. Fluid filtration decreased when the ductus was closed.",
"   </p>",
"   <p>",
"    In preterm infants, a clinically significant PDA is associated with increased risk of pulmonary edema, pulmonary hemorrhage, and bronchopulmonary dysplasia, and a decrease in pulmonary function. PDA closure improves pulmonary compliance and ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10685908\">",
"     'Significant PDA'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685865\">",
"    <span class=\"h3\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with PDA often have pulmonary edema due to the increased filtration of lung fluid into the interstitium from increased pulmonary blood flow and pressure (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71213 \" href=\"UTD.htm?37/57/38815\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685872\">",
"    <span class=\"h3\">",
"     Pulmonary hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased pulmonary blood flow and ductal shunting may contribute to pulmonary hemorrhage. Among 126 babies born before 30 weeks gestation, 12 patients with pulmonary hemorrhage compared to those without pulmonary hemorrhage had greater median PDA diameter (2.0 versus 0.5 mm) and pulmonary blood flow (326 versus 237",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per minute) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/30\">",
"     30",
"    </a>",
"    ]. Ductal diameter measured at five hours of age also was greater in the infants who subsequently developed pulmonary hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685880\">",
"    <span class=\"h3\">",
"     Bronchopulmonary dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinically significant PDA is associated with the development of pulmonary edema and subsequent bronchopulmonary dysplasia (BPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. In one series of 865 VLBW infants who survived to 36 weeks postmenstrual age, a diagnosis of PDA in the first week after birth was associated with a 4.5-fold increase in BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term pulmonary effects may be related to the duration of ductal patency, even when the PDA is asymptomatic as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 20 infants of approximately 28 weeks gestational age, those who had an asymptomatic PDA detected by echocardiogram at 54 hours of age had higher carbon dioxide tensions than did those whose ductus had closed (43 versus 36 mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/34\">",
"       34",
"      </a>",
"      ]. These infants had longer durations of oxygen supplementation (26 versus 4 days) and mechanical ventilation (eight versus two days) than did those whose PDAs closed earlier.",
"     </li>",
"     <li>",
"      In a case-control study, 28 infants with persistent PDA (n = 28) greater than 21 days were more likely to develop severe BPD compared with 56 matched infants whose PDA closed before 21 days of age (60 versus 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/35\">",
"       35",
"      </a>",
"      ]. In addition, patients with persistent PDA had higher rates of morbidities, including increased days of mechanical ventilation, oxygen supplemental therapy, and length of hospital stay, and increased rates of retinopathy of prematurity and necrotizing enterocolitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1002?source=see_link&amp;anchor=H1214695#H1214695\">",
"       \"Management of patent ductus arteriosus in premature infants\", section on 'Outcome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical improvement seen in human infants after PDA closure is supported by studies using a baboon model of BPD. Preterm animals treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    at 24 hours of life compared to controls had improved pulmonary mechanics (lower",
"    <span class=\"nowrap\">",
"     pulmonary/systemic",
"    </span>",
"    flow ratio, lower left ventricular end diastolic diameter, higher systemic blood pressure), decreased total lung water, and increased epithelial sodium channel expression [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, controls had morphologic features of alveolar arrest, known as the &ldquo;new BPD&rdquo;, that were not present in treated animals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there is a strong association between PDA and BPD, data from the Trial of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     Indomethacin",
"    </a>",
"    Prophylaxis in Preterms (TIPP) study demonstrated that prophylactic intervention to prevent PDA did not decrease the incidence of BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/37\">",
"     37",
"    </a>",
"    ]. A reexamination of the only trial of prophylactic ductal ligation actually showed a higher risk of BPD in the ligated infants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, while it would be logical to assume that PDA may be a contributing factor to the development of BPD because of the strong association between the two, such a causal link has not been established and may not exist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685887\">",
"    <span class=\"h2\">",
"     Systemic and cerebral blood flow effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although preterm animals and infants with a PDA have an increased cardiac output, the postductal blood flow is reduced because of left-to-right shunting. Moderate and large ductal steals result in reduced oxygen delivery and perfusion to vital organs in infants with PDA compared to infants without a PDA as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebral blood flow and oxygenation &ndash; Moderate or large left-to-right shunts reduce cerebral blood flow and oxygenation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a study of 10 preterm infants with a PDA and matched controls, abnormal cerebral blood flow patterns were detected by gated pulsed-Doppler examinations in seven infants with a large PDA [",
"      <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/39\">",
"       39",
"      </a>",
"      ]. In the cerebral arteries of these patients, diastolic flow was retrograde in three, and decreased or absent in the other four. After PDA closure, diastolic flow was antegrade similar to controls and infants with small PDAs.",
"     </li>",
"     <li>",
"      In a study of 20 infants with a PDA and matched controls, infants with a PDA had lower cerebral oxygen saturation and mean arterial blood pressure (BP), and higher fractional tissue oxygen extraction compared with controls [",
"      <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/40\">",
"       40",
"      </a>",
"      ]. After PDA closure, there were no differences in these parameters between the two groups.",
"     </li>",
"     <li>",
"      These changes in cerebral blood flow and oxygenation may contribute to the increased risk of IVH seen in preterm infants with PDA compared to those without PDA [",
"      <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\", section on 'Cerebral blood flow instability'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aorta blood flow &ndash; In one study, VLBW infants with a hemodynamically significant PDA had higher left ventricular output and lower abdominal aortic blood flow than did infants without a PDA, although cerebral blood flow was comparable [",
"      <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/42\">",
"       42",
"      </a>",
"      ]. These changes may contribute to the increased incidence of necrotizing enterocolitis seen in preterm infants with PDA compared to those with no PDA [",
"      <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathology and pathogenesis of necrotizing enterocolitis in newborns\", section on 'Circulatory instability'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685894\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature infants with a hemodynamically significant PDA typically develop signs during the first two to three days after birth. Clinical findings may develop earlier in infants treated with surfactant because the reduction in pulmonary vascular resistance associated with improved lung function results in increased left-to-right shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Heart failure may rarely develop later in the first week.",
"   </p>",
"   <p>",
"    The risk of hemodynamically significant PDA increases with decreasing gestational age and birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Approximately 80 percent of ELBW infants with birth weight &lt;1000 g who have a murmur progress to large, persistent PDAs. The risk is lower in larger infants. In a few patients, asymptomatic PDA can persist with closure occurring after 10 days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical findings seen in the majority of preterm infants with a hemodynamically significant PDA include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Murmur &ndash; The murmur often is heard over the entire precordium, but best in the left infraclavicular region and upper left sternal border. Because of high pulmonary vascular resistance after birth, aortic pressure is greater than pulmonary pressure during systole but may not be so during diastole. As a result, the murmur initially may be heard only in systole and have an ejection quality. As pulmonary vascular resistance and pulmonary artery pressure fall, aortic pressure is higher than pulmonary artery pressure during both systole and diastole, producing continuous flow through the ductus and a continuous (machinery) murmur.",
"      <br/>",
"      <br/>",
"      Occasionally, a PDA is clinically \"silent\" with absence of a murmur, especially in the first three days after birth [",
"      <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. In these cases, the primary findings associated with development of a significant PDA are deterioration of respiratory status despite surfactant treatment, circulatory instability, or cardiac enlargement on chest radiograph (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71213 \" href=\"UTD.htm?37/57/38815\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Prominent left ventricular impulse.",
"     </li>",
"     <li>",
"      Bounding pulses.",
"     </li>",
"     <li>",
"      Widened pulse pressure that is greater than 25 mmHg or if the difference between the systolic and diastolic blood pressure (BP) exceeds half of the value of the systolic BP.",
"     </li>",
"     <li>",
"      Noncardiovascular findings include tachypnea, apnea, increased carbon dioxide retention, or increased requirements for mechanical ventilation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No single finding is specific for a PDA. Similar findings can occur with other cardiac lesions, such as an aortic-pulmonary window or an arteriovenous fistula.",
"   </p>",
"   <p>",
"    Complications of prematurity that occur more commonly among infants with PDA include",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/38,41,43,53-56\">",
"     38,41,43,53-56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary edema",
"     </li>",
"     <li>",
"      Bronchopulmonary dysplasia (BPD)",
"     </li>",
"     <li>",
"      Necrotizing enterocolitis (NEC)",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Intraventricular hemorrhage (IVH)",
"     </li>",
"     <li>",
"      Prolonged ventilator",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oxygen support",
"     </li>",
"     <li>",
"      Longer duration of hospitalization",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685901\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PDA is usually based upon its characteristic clinical findings and confirmed by echocardiography. The combination of two-dimensional echocardiographic imaging and Doppler color flow mapping is both sensitive and specific for the identification of PDA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/57\">",
"     57",
"    </a>",
"    ]. At our institution, an echocardiogram is performed to confirm the presence of a clinically significant PDA before initiating therapy. Other centers, especially those without onsite readily available echocardiography, may elect to treat presumptively based on clinical findings and perform echocardiography only if there is a contradiction to the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    therapy, if there is no response to medical therapy, or there is a recurrence of findings after medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chest radiography may be helpful in the diagnosis and evaluation of PDA in preterm infants but it is less sensitive and specific than echocardiography. In patients with moderate and large PDAs, the chest radiograph shows increasing cardiac enlargement and pulmonary vascular markings as the left-to-right shunting increases (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71213 \" href=\"UTD.htm?37/57/38815\">",
"     image 1",
"    </a>",
"    ). The electrocardiogram is not helpful in the diagnosis of PDA in preterm infants.",
"   </p>",
"   <p>",
"    In preterm infants without a murmur or other physical findings suggestive of PDA but with an unexplained deterioration in respiratory status, an echocardiogram is necessary to determine whether a &ldquo;silent&rdquo; PDA is present. (See",
"    <a class=\"local\" href=\"#H10685894\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10685908\">",
"    <span class=\"h2\">",
"     Significant PDA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the interventions used to close PDA can have significant adverse effects, the decision to intervene should be based upon a hemodynamically significant PDA, which if left untreated leads to pulmonary overcirculation, which increases the risk of developing pulmonary edema, pulmonary hemorrhage, and BPD, and systemic undercirculation, which increases the risk of NEC, and systemic hypoperfusion. However, it has not been possible to establish stringent echocardiographic criteria that directly correlate with end-organ hypoperfusion and clinical morbidity.",
"   </p>",
"   <p>",
"    The size of the PDA measured by echocardiography is generally used to determine whether or not a PDA is hemodynamically significant in preterm infants. One commonly used measure is a transductal diameter that exceeds 1.5 mm or 1.4",
"    <span class=\"nowrap\">",
"     mm/kg",
"    </span>",
"    body [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In one series of mechanically ventilated infants younger than 30 weeks gestation, a ductal diameter of 1.5 mm or greater at 7 to 31 hours of life predicted a significant PDA with 83 percent sensitivity and 90 percent specificity for a PDA that was treated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the use of the transductal diameter as the sole measure of a significant PDA has been increasingly scrutinized, partly as recent trials utilizing this threshold have not resulted in a reduction of neonatal morbidity associated with PDA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. As an alternative, a proposed staging system to detect clinically significant PDA uses both clinical findings (eg, oxygenation index, degree of respiratory support, chest radiography, and end-organ function) and echocardiographic measurements to classify the severity of PDA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others have used the PDA:left pulmonary artery ratio to define large (&gt;1), moderate (&lt;1 but &gt;0.5), and small (0.5) PDAs in the first four days of postnatal life to predict which infants would receive treatment for PDA closure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/63\">",
"     63",
"    </a>",
"    ]. Those with large or moderate PDAs are &nbsp;15 times more likely to receive treatment, and those with small PDAs have a high likelihood of spontaneous resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/64\">",
"     64",
"    </a>",
"    ]. Sensitivity, specificity, and positive predictive value of a large or moderate PDA:LPA ratio in the first four days were 80, 86, and 92 percent respectively for infants &lt;27 weeks gestation.",
"   </p>",
"   <p>",
"    There is a strong correlation between the ductal diameter and flow patterns in determining the severity of PDA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/50/15145/abstract/65\">",
"     65",
"    </a>",
"    ], and it is reasonable to use both methods to decide on whether to initiate intervention.",
"   </p>",
"   <p>",
"    In our institution, we use a combination of factors to determine whether a PDA is hemodynamically significant and warrants intervention. These include the relative size of the ductus to the aorta, the magnitude of flow across the ductus, and the degree of left heart overflow determined by echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728294868\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ductus arteriosus (DA) is a fetal vascular connection between the main pulmonary artery and the aorta that normally closes soon after birth (",
"    <a class=\"graphic graphic_figure graphicRef65828 \" href=\"UTD.htm?10/31/10739\">",
"     figure 1",
"    </a>",
"    ). A patent ductus arteriosus (PDA) occurs when the ductus fails to completely close after delivery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the fetus, blood from the right ventricle passes away from the constricted pulmonary arteries, which have a high vascular resistance, and flows into the DA and descending aorta. With the onset of respiration after delivery, the lungs expand and the systemic oxygen saturation rises, resulting in pulmonary vasodilatation and a drop in pulmonary vascular resistance. At the same time, systemic resistance rises with the removal of the placenta. These factors lead to a sudden reversal of blood flow in the DA from right-to-left to left-to-right. (See",
"      <a class=\"local\" href=\"#H10685787\">",
"       'Fetal and transitional ductal circulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ductal closure is delayed in preterm infants and the risk of PDA is inversely proportional to gestational age. Respiratory illness is also associated with an increased risk of PDA. (See",
"      <a class=\"local\" href=\"#H10685837\">",
"       'Preterm infants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In infants with a PDA, the left-to-right shunting of blood results in an excessive blood flow through the pulmonary circulation and hypoperfusion of the systemic circulation. The physiologic consequences of this &ldquo;ductal steal&rdquo; depend upon the size of the shunt and the response of the heart, lungs, and other organs to the shunt. Moderate to large shunts may result in pulmonary edema and hemorrhage, bronchopulmonary dysplasia (BPD), and decreased perfusion and oxygen delivery to end-organs. (See",
"      <a class=\"local\" href=\"#H10685851\">",
"       'Physiologic effects and clinical implications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following clinical features are seen in preterm infants with a PDA. (See",
"      <a class=\"local\" href=\"#H10685894\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Heart murmur, which may initially be heard only in systole and have an ejection quality. As pulmonary vascular resistance and pulmonary artery pressure fall, aortic pressure becomes higher than pulmonary artery pressure during both systole and diastole, which produces continuous flow through the ductus and a continuous (machinery) murmur.",
"     </li>",
"     <li>",
"      Other cardiovascular findings include a prominent left ventricular impulse, bounding pulses, and widened pulse pressure.",
"     </li>",
"     <li>",
"      Noncardiovascular findings include tachypnea, apnea, increased carbon dioxide retention, or increased requirements for mechanical ventilation.",
"     </li>",
"     <li>",
"      Complications of prematurity, such as BPD, necrotizing enterocolitis, and intraventricular hemorrhage, occur more commonly among infants with a PDA than in infants without a PDA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of PDA is usually based upon its characteristic clinical findings and confirmed by echocardiography. (See",
"      <a class=\"local\" href=\"#H10685901\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/1\">",
"      Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001; 107:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/2\">",
"      Rudolph AM. The changes in the circulation after birth. Their importance in congenital heart disease. Circulation 1970; 41:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/3\">",
"      Smith GC. The pharmacology of the ductus arteriosus. Pharmacol Rev 1998; 50:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/4\">",
"      Clyman RI, Mauray F, Roman C, et al. Circulating prostaglandin E2 concentrations and patent ductus arteriosus in fetal and neonatal lambs. J Pediatr 1980; 97:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/5\">",
"      Clyman RI, Mauray F, Roman C, et al. Effects of antenatal glucocorticoid administration on ductus arteriosus of preterm lambs. Am J Physiol 1981; 241:H415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/6\">",
"      Wright LL, Verter J, Younes N, et al. Antenatal corticosteroid administration and neonatal outcome in very low birth weight infants: the NICHD Neonatal Research Network. Am J Obstet Gynecol 1995; 173:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/7\">",
"      Moise KJ Jr. Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol 1993; 168:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/8\">",
"      Vermillion ST, Scardo JA, Lashus AG, Wiles HB. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 1997; 177:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/9\">",
"      Clyman RI, Waleh N, Black SM, et al. Regulation of ductus arteriosus patency by nitric oxide in fetal lambs: the role of gestation, oxygen tension, and vasa vasorum. Pediatr Res 1998; 43:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/10\">",
"      Gittenberger-de Groot AC, Strengers JL, Mentink M, et al. Histologic studies on normal and persistent ductus arteriosus in the dog. J Am Coll Cardiol 1985; 6:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/11\">",
"      Gittenberger-de Groot AC. Persistent ductus arteriosus: most probably a primary congenital malformation. Br Heart J 1977; 39:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/12\">",
"      Clyman RI, Chan CY, Mauray F, et al. Permanent anatomic closure of the ductus arteriosus in newborn baboons: the roles of postnatal constriction, hypoxia, and gestation. Pediatr Res 1999; 45:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/13\">",
"      Sandner P, Wolf K, Bergmaier U, et al. Induction of VEGF and VEGF receptor gene expression by hypoxia: divergent regulation in vivo and in vitro. Kidney Int 1997; 51:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/14\">",
"      Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995; 95:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/15\">",
"      Waleh N, Seidner S, McCurnin D, et al. Anatomic closure of the premature patent ductus arteriosus: The role of CD14+/CD163+ mononuclear cells and VEGF in neointimal mound formation. Pediatr Res 2011; 70:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/16\">",
"      Gentile R, Stevenson G, Dooley T, et al. Pulsed Doppler echocardiographic determination of time of ductal closure in normal newborn infants. J Pediatr 1981; 98:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/17\">",
"      Reller MD, Rice MJ, McDonald RW. Review of studies evaluating ductal patency in the premature infant. J Pediatr 1993; 122:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/18\">",
"      Dudell GG, Gersony WM. Patent ductus arteriosus in neonates with severe respiratory disease. J Pediatr 1984; 104:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/19\">",
"      Koch J, Hensley G, Roy L, et al. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006; 117:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/20\">",
"      Clyman RI. Ductus arteriosus: current theories of prenatal and postnatal regulation. Semin Perinatol 1987; 11:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/21\">",
"      Clyman RI, Mauray F, Roman C, et al. Effect of gestational age on ductus arteriosus response to circulating prostaglandin E2. J Pediatr 1983; 102:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/22\">",
"      Quinn D, Cooper B, Clyman RI. Factors associated with permanent closure of the ductus arteriosus: a role for prolonged indomethacin therapy. Pediatrics 2002; 110:e10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/23\">",
"      Weiss H, Cooper B, Brook M, et al. Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin. J Pediatr 1995; 127:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/24\">",
"      Vick GW 3rd, Satterwhite C, Cassady G, et al. Radionuclide angiography in the evaluation of ductal shunts in preterm infants. J Pediatr 1982; 101:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/25\">",
"      Alpan G, Scheerer R, Bland R, Clyman R. Patent ductus arteriosus increases lung fluid filtration in preterm lambs. Pediatr Res 1991; 30:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/26\">",
"      Stefano JL, Abbasi S, Pearlman SA, et al. Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome. Effects of pulmonary compliance and ventilation. Am Rev Respir Dis 1991; 143:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/27\">",
"      Yeh TF, Thalji A, Luken L, et al. Improved lung compliance following indomethacin therapy in premature infants with persistent ductus arteriosus. Chest 1981; 80:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/28\">",
"      Gerhardt T, Bancalari E. Lung compliance in newborns with patent ductus arteriosus before and after surgical ligation. Biol Neonate 1980; 38:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/29\">",
"      Szymankiewicz M, Hodgman JE, Siassi B, Gadzinowski J. Mechanics of breathing after surgical ligation of patent ductus arteriosus in newborns with respiratory distress syndrome. Biol Neonate 2004; 85:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/30\">",
"      Kluckow M, Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr 2000; 137:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/31\">",
"      Todd DA, Jana A, John E. Chronic oxygen dependency in infants born at 24-32 weeks' gestation: the role of antenatal and neonatal factors. J Paediatr Child Health 1997; 33:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/32\">",
"      Hagan R, Minutillo C, French N, et al. Neonatal chronic lung disease, oxygen dependency, and a family history of asthma. Pediatr Pulmonol 1995; 20:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/33\">",
"      Marshall DD, Kotelchuck M, Young TE, et al. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 1999; 104:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/34\">",
"      Yanowitz TD, Yao AC, Pettigrew KD, et al. Postnatal hemodynamic changes in very-low-birthweight infants. J Appl Physiol 1999; 87:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/35\">",
"      Salde&ntilde;o YP, Favareto V, Mirpuri J. Prolonged persistent patent ductus arteriosus: potential perdurable anomalies in premature infants. J Perinatol 2012; 32:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/36\">",
"      McCurnin D, Seidner S, Chang LY, et al. Ibuprofen-induced patent ductus arteriosus closure: physiologic, histologic, and biochemical effects on the premature lung. Pediatrics 2008; 121:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/37\">",
"      Schmidt B, Roberts RS, Fanaroff A, et al. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr 2006; 148:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/38\">",
"      Clyman R, Cassady G, Kirklin JK, et al. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Pediatr 2009; 154:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/39\">",
"      Martin CG, Snider AR, Katz SM, et al. Abnormal cerebral blood flow patterns in preterm infants with a large patent ductus arteriosus. J Pediatr 1982; 101:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/40\">",
"      Lemmers PM, Toet MC, van Bel F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics 2008; 121:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/41\">",
"      Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/42\">",
"      Shimada S, Kasai T, Konishi M, Fujiwara T. Effects of patent ductus arteriosus on left ventricular output and organ blood flows in preterm infants with respiratory distress syndrome treated with surfactant. J Pediatr 1994; 125:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/43\">",
"      Cassady G, Crouse DT, Kirklin JW, et al. A randomized, controlled trial of very early prophylactic ligation of the ductus arteriosus in babies who weighed 1000 g or less at birth. N Engl J Med 1989; 320:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/44\">",
"      Sepp&auml;nen M, K&auml;&auml;p&auml; P, Kero P. Acute effects of synthetic surfactant replacement on pulmonary blood flow in neonatal respiratory distress syndrome. Am J Perinatol 1994; 11:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/45\">",
"      Clyman RI, Jobe A, Heymann M, et al. Increased shunt through the patent ductus arteriosus after surfactant replacement therapy. J Pediatr 1982; 100:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/46\">",
"      K&auml;&auml;p&auml; P, Sepp&auml;nen M, Kero P, Saraste M. Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. J Pediatr 1993; 123:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/47\">",
"      Ellison RC, Peckham GJ, Lang P, et al. Evaluation of the preterm infant for patent ductus arteriosus. Pediatrics 1983; 71:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/48\">",
"      Furzan JA, Reisch J, Tyson JE, et al. Incidence and risk factors for symptomatic patent ductus arteriosus among inborn very-low-birth-weight infants. Early Hum Dev 1985; 12:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/49\">",
"      Mouzinho AI, Rosenfeld CR, Risser R. Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989. Early Hum Dev 1991; 27:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/50\">",
"      Reller MD, Lorenz JM, Kotagal UR, et al. Hemodynamically significant PDA: an echocardiographic and clinical assessment of incidence, natural history, and outcome in very low birth weight infants maintained in negative fluid balance. Pediatr Cardiol 1985; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/51\">",
"      Hammerman C, Strates E, Valaitis S. The silent ductus: its precursors and its aftermath. Pediatr Cardiol 1986; 7:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/52\">",
"      Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health 1994; 30:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/53\">",
"      Cotton RB, Stahlman MT, Kovar I, Catterton WZ. Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr 1978; 92:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/54\">",
"      Mahony L, Carnero V, Brett C, et al. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants. N Engl J Med 1982; 306:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/55\">",
"      Thibeault DW, Emmanouilides GC, Nelson RJ, et al. Patent ductus arteriosus complicating the respiratory distress syndrome in preterm infants. J Pediatr 1975; 86:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/56\">",
"      Jacob J, Gluck L, DiSessa T, et al. The contribution of PDA in the neonate with severe RDS. J Pediatr 1980; 96:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/57\">",
"      Huhta JC, Cohen M, Gutgesell HP. Patency of the ductus arteriosus in normal neonates: two-dimensional echocardiography versus Doppler assessment. J Am Coll Cardiol 1984; 4:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/58\">",
"      Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010; 125:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/59\">",
"      Harling S, Hansen-Pupp I, Baigi A, Pesonen E. Echocardiographic prediction of patent ductus arteriosus in need of therapeutic intervention. Acta Paediatr 2011; 100:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/60\">",
"      Kluckow M, Evans N. Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation. J Pediatr 1995; 127:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/61\">",
"      McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007; 92:F424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/62\">",
"      Bose CL, Laughon MM. Patent ductus arteriosus: lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed 2007; 92:F498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/63\">",
"      Ramos FG, Rosenfeld CR, Roy L, et al. Echocardiographic predictors of symptomatic patent ductus arteriosus in extremely-low-birth-weight preterm neonates. J Perinatol 2010; 30:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/64\">",
"      Thankavel PP, Rosenfeld CR, Christie L, Ramaciotti C. Early echocardiographic prediction of ductal closure in neonates &le; 30 weeks gestation. J Perinatol 2013; 33:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/50/15145/abstract/65\">",
"      Cond&ograve; M, Evans N, Bell&ugrave; R, Kluckow M. Echocardiographic assessment of ductal significance: retrospective comparison of two methods. Arch Dis Child Fetal Neonatal Ed 2012; 97:F35.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5057 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15145=[""].join("\n");
var outline_f14_50_15145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H728294868\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10685779\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10685787\">",
"      FETAL AND TRANSITIONAL DUCTAL CIRCULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10685794\">",
"      Patency of the ductus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10685801\">",
"      - Prostaglandin E2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10685808\">",
"      - Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10685815\">",
"      Ductal constriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10685822\">",
"      Permanent closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10685829\">",
"      - Term infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10685837\">",
"      - Preterm infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10685844\">",
"      - Reopening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10685851\">",
"      PHYSIOLOGIC EFFECTS AND CLINICAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10685858\">",
"      Pulmonary effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10685865\">",
"      - Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10685872\">",
"      - Pulmonary hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10685880\">",
"      - Bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10685887\">",
"      Systemic and cerebral blood flow effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10685894\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10685901\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10685908\">",
"      Significant PDA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H728294868\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5057\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5057|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/57/38815\" title=\"diagnostic image 1\">",
"      PDA before after indomethacin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5057|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/31/10739\" title=\"figure 1\">",
"      Pathophysiology PDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15032\" title=\"figure 2\">",
"      Fetal circulation 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/39/10864\" title=\"figure 3\">",
"      Fetal cardiac output distributi",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1002?source=related_link\">",
"      Management of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=related_link\">",
"      Pathology and pathogenesis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8502?source=related_link\">",
"      Physiologic transition from intrauterine to extrauterine life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_50_15146="Paroxetine: Drug information";
var content_f14_50_15146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Paroxetine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/12/17606?source=see_link\">",
"    see \"Paroxetine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18361?source=see_link\">",
"    see \"Paroxetine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Paxil CR&reg;;",
"     </li>",
"     <li>",
"      Paxil&reg;;",
"     </li>",
"     <li>",
"      Pexeva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Paroxetine&reg;;",
"     </li>",
"     <li>",
"      CO Paroxetine;",
"     </li>",
"     <li>",
"      Dom-Paroxetine;",
"     </li>",
"     <li>",
"      Mylan-Paroxetine;",
"     </li>",
"     <li>",
"      Novo-Paroxetine;",
"     </li>",
"     <li>",
"      Paxil CR&reg;;",
"     </li>",
"     <li>",
"      Paxil&reg;;",
"     </li>",
"     <li>",
"      PHL-Paroxetine;",
"     </li>",
"     <li>",
"      PMS-Paroxetine;",
"     </li>",
"     <li>",
"      ratio-Paroxetine;",
"     </li>",
"     <li>",
"      Riva-Paroxetine;",
"     </li>",
"     <li>",
"      Sandoz-Paroxetine;",
"     </li>",
"     <li>",
"      Teva-Paroxetine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F206637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Selective Serotonin Reuptake Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F206599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Major depressive disorder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Paxil&reg;, Pexeva&reg;:",
"     </i>",
"     Initial: 20 mg once daily, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Paxil CR&reg;:",
"     </i>",
"     Initial: 25 mg once daily; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum dose: 62.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Generalized anxiety disorder (Paxil&reg;, Pexeva&reg;):",
"     </b>",
"     Oral: Initial: 20 mg once daily, preferably in the morning (if dose is increased, adjust in increments of 10 mg/day at 1-week intervals); doses of 20-50 mg/day were used in clinical trials, however, no greater benefit was seen with doses &gt;20 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Obsessive-compulsive disorder (Paxil&reg;, Pexeva&reg;):",
"     </b>",
"     Oral: Initial: 20 mg once daily, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; recommended dose: 40 mg/day; range: 20-60 mg/day; maximum dose: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Panic disorder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Paxil&reg;, Pexeva&reg;:",
"     </i>",
"     Initial: 10 mg once daily, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; recommended dose: 40 mg/day; range: 10-60 mg/day; maximum dose: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Paxil CR&reg;:",
"     </i>",
"     Initial: 12.5 mg once daily; increase if needed by 12.5 mg/day at intervals of at least 1 week; maximum dose: 75 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Premenstrual dysphoric disorder (Paxil CR&reg;):",
"     </b>",
"     Oral: Initial: 12.5 mg once daily in the morning; may be increased to 25 mg/day; dosing changes should occur at intervals of at least 1 week. May be given daily throughout the menstrual cycle or limited to the luteal phase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Post-traumatic stress disorder (Paxil&reg;):",
"     </b>",
"     Oral: Initial: 20 mg once daily, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; range: 20-50 mg. Limited data suggest doses of 40 mg/day were not more efficacious than 20 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Social anxiety disorder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Paxil&reg;:",
"     </i>",
"     Initial: 20 mg once daily, preferably in the morning; recommended dose: 20 mg/day; range: 20-60 mg/day; doses &gt;20 mg may not have additional benefit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Paxil CR&reg;:",
"     </i>",
"     Initial: 12.5 mg once daily, preferably in the morning; may be increased by 12.5 mg/day at intervals of at least 1 week; maximum dose: 37.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Menopause-associated vasomotor symptoms (unlabeled use, Paxil CR&reg;):",
"     </b>",
"     Oral: 12.5-25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Upon discontinuation of paroxetine therapy, gradually taper dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil&reg;, Pexeva&reg;: 10 mg/day at weekly intervals; when 20 mg/day dose is reached, continue for 1 week before treatment is discontinued. Some patients may need to be titrated to 10 mg/day for 1 week before discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil CR&reg;: Patients receiving 37.5 mg/day in clinical trials had their dose decreased by 12.5 mg/day to a dose of 25 mg/day and remained at a dose of 25 mg/day for 1 week before treatment was discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of paroxetine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing paroxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate paroxetine in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving paroxetine and potential benefits outweigh potential risks, discontinue paroxetine promptly and administer linezolid or I.V. methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume paroxetine 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F206618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18361?source=see_link\">",
"      see \"Paroxetine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Obsessive-compulsive disorder (unlabeled use):",
"     </b>",
"     Children &ge;8 years: Oral: Initial: 10 mg/day; titrate every 7-14 days in 10 mg/day increments as necessary to a maximum 60 mg/day; trials have typically continued for a 10- to 12-week treatment course (Geller, 2004; Rosenberg, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Social anxiety disorder (unlabeled use):",
"     </b>",
"     Children &ge;8 years: Oral: Initial: 2.5-10 mg/day; titrate every &ge;7 days in 5-10 mg/day increments to a maximum of 50 mg/day; trials have typically continued for a 16-week treatment course (Mancini, 1999; Wagner, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F206600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Major depressive disorder, obsessive compulsive disorder, panic attack, social anxiety disorder:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Paxil&reg;, Pexeva&reg;:",
"     </i>",
"     Oral: Initial: 10 mg/day; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Paxil CR&reg;:",
"     </i>",
"     Initial: 12.5 mg/day; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Upon discontinuation of paroxetine therapy, gradually taper dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil&reg;, Pexeva&reg;: 10 mg/day at weekly intervals; when 20 mg/day dose is reached, continue for 1 week before treatment is discontinued. Some patients may need to be titrated to 10 mg/day for 1 week before discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil CR&reg;: Patients receiving 37.5 mg/day in clinical trials had their dose decreased by 12.5 mg/day to a dose of 25 mg/day and remained at a dose of 25 mg/day for 1 week before treatment was discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F206601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute: Plasma concentration is 2 times that seen in normal function. There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Mean plasma concentration is ~4 times that seen in normal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil&reg;, Pexeva&reg;: Initial: 10 mg/day; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil CR&reg;: Initial: 12.5 mg/day; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F206602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Adults: In hepatic dysfunction, plasma concentration is 2 times that seen in normal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe impairment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Paxil&reg;, Pexeva&reg;: Initial: 10 mg/day; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Paxil CR&reg;: Initial: 12.5 mg/day; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as hydrochloride [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil&reg;: 10 mg/5 mL (250 mL) [contains propylene glycol; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride [strength expressed as base]: 10 mg, 20 mg, 30 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil&reg;: 10 mg, 20 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil&reg;: 30 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as mesylate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pexeva&reg;: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pexeva&reg;: 20 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pexeva&reg;: 30 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release, enteric coated, oral, as hydrochloride [strength expressed as base]: 12.5 mg, 25 mg, 37.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paxil CR&reg;: 12.5 mg, 25 mg, 37.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, enteric coated, oral, as hydrochloride [strength expressed as base]: 12.5 mg, 25 mg, 37.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes suspension, tablet (mesylate)",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Paxil CR&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088676.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088676.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pexeva&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088684.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088684.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F206571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals, preferably in the morning. Do not crush, break, or chew controlled release tablets.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive disorder (MDD); treatment of panic disorder with or without agoraphobia; obsessive-compulsive disorder (OCD); social anxiety disorder (social phobia); generalized anxiety disorder (GAD); post-traumatic stress disorder (PTSD); premenstrual dysphoric disorder (PMDD)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F206633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be useful in eating disorders, impulse control disorders; vasomotor symptoms of menopause; treatment of obsessive-compulsive disorder (OCD) in children; treatment of mild dementia-associated agitation in nonpsychotic patients; treatment of paraphilia/hypersexuality",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F206646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PARoxetine may be confused with FLUoxetine, PACLitaxel, piroxicam, pyridoxine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Paxil&reg; may be confused with Doxil&reg;, PACLitaxel, Plavix&reg;, PROzac&reg;, Taxol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (SIADH: Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F206635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency varies by dose and indication. Adverse reactions reported as a composite of all indications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (15% to 24%), insomnia (11% to 24%), headache (17% to 18%), dizziness (6% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (3% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (19% to 26%), xerostomia (9% to 18%), constipation (5% to 16%), diarrhea (9% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Ejaculatory disturbances (13% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (12% to 22%), tremor (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (5% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (2% to 4%), chest pain (3%), palpitation (2% to 3%), hypertension (&ge;1%), tachycardia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Nervousness (4% to 9%), anxiety (5%), agitation (3% to 5%), abnormal dreams (3% to 4%), concentration impaired (3% to 4%), yawning (2% to 4%), depersonalization (&le;3%), amnesia (2%), chills (2%), emotional lability (&ge;1%), vertigo (&ge;1%), confusion (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2% to 3%), pruritus (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Orgasmic disturbance (2% to 9%), dysmenorrhea (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased (5% to 9%), dyspepsia (2% to 5%), flatulence (4%), abdominal pain (4%), appetite increased (2% to 4%), vomiting (2% to 3%), taste perversion (2%), weight gain (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Genital disorder (male 10%; female 2% to 9%), impotence (2% to 9%), urinary frequency (2% to 3%), urinary tract infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (4%), myalgia (2% to 4%), back pain (3%), myoclonus (2% to 3%), myopathy (2%), myasthenia (1%), arthralgia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (4%), abnormal vision (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory disorder (&le;7%), pharyngitis (4%), sinusitis (&le;4%), rhinitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (5% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, adrenergic syndrome, akinesia, alkaline phosphatase increased, allergic reaction, anaphylaxis, anemias (various), angina pectoris, angioedema, aphasia, aphthous stomatitis, arrhythmias (atrial and ventricular), arthrosis, asthma, bilirubinemia, bleeding time increased, blood dyscrasias, bloody diarrhea, bradycardia, bronchitis, bulimia, BUN increased, bundle branch block, cardiospasm, cataract, cellulitis, cerebral ischemia, cerebrovascular accident, cholelithiasis, colitis, congestive heart failure, creatine phosphokinase increased, deafness, delirium, diabetes mellitus, drug dependence, dyskinesia, dysphagia, eclampsia, emphysema, erythema, exfoliative dermatitis, extrapyramidal syndrome, fecal impactions, fungal dermatitis, gamma globulins increased, gastroenteritis, glaucoma, goiter, Guillain-Barr&eacute; syndrome, hallucinations, hematemesis, hematoma, hemorrhage, hemoptysis, hepatic necrosis, hepatitis, hypercholesteremia, hyper-/hypoglycemia, hyper-/hypothyroidism, hypotension, ileus, intestinal obstruction, ketosis, lactic dehydrogenase increased, liver function tests abnormal, low cardiac output, lung fibrosis, lymphadenopathy, meningitis, MI, migraine, myelitis, myocardial ischemia, neuroleptic malignant syndrome, neuropathy, osteoporosis, pancreatitis, pancytopenia, peptic ulcer, peritonitis, phlebitis, pneumonia, platelet count abnormalities, pulmonary edema, pulmonary embolus, pulmonary hypertension, seizure, sepsis, serotonin syndrome, sperm activity altered, sperm DNA fragmentation (abnormal) increased, status epilepticus, Stevens-Johnson syndrome, suicidal tendencies, syncope, tetany, thrombophlebitis, thrombosis, torsade de pointes, toxic epidermal necrolysis, vasculitic syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F206574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to paroxetine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either paroxetine or the MAO inhibitor); initiation of paroxetine in a patient receiving linezolid or intravenous methylene blue; concurrent use with thioridazine or pimozide",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F206555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Paroxetine is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants (for any indication) should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Akathisia: Inability to remain still due to feelings of agitation or restlessness has been observed with paroxetine and other SSRIs. Usually occurs within the first few weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Has low potential for sedation and anticholinergic effects relative to cyclic antidepressants; however among the SSRI class these effects are relatively higher.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin, NSAIDs, warfarin or other anticoagulants. Bleeding related to SSRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Volume depletion and/or concurrent use of diuretics likely increases risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; paroxetine has not been systemically evaluated in patients with a recent history of MI or unstable heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Paroxetine is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Narrow-angle glaucoma: May cause mydriasis which can exacerbate narrow angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agents which lower seizure threshold: Concurrent therapy of paroxetine with these drugs may increase the risk of seizure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients;  may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Medication associated with potent anticholinergic properties which may be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Avoid use in the first trimester.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: May cause dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, electric shock-like sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. Upon discontinuation of paroxetine therapy, gradually taper dose. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, then resuming the previous dose with a more gradual taper should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F206630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2B6 (moderate), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (strong), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of PARoxetine. PARoxetine may decrease the serum concentration of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: PARoxetine may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. PARoxetine may increase the serum concentration of ARIPiprazole.  Management: Aripiprazole dose adjustment is recommended, except when used adjunctively for depression. Consult full interaction monograph or aripiprazole prescribing information for complete details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Asenapine: May increase the serum concentration of PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Acebutolol; Atenolol; Betaxolol (Ophthalmic); Betaxolol (Systemic); Bisoprolol; Carteolol (Ophthalmic); Esmolol; Labetalol; Levobunolol; Metipranolol; Nadolol; Penbutolol; Sotalol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Moderate) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. PARoxetine may increase the serum concentration of DULoxetine. Management: Coadminister with caution.  If duloxetine and paroxetine are used in combination, monitor for signs and symptoms of serotonin toxicity/serotonin syndrome, as well as other toxic effects of duloxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May decrease the serum concentration of PARoxetine. The active metabolite amprenavir is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: PARoxetine may decrease serum concentrations of the active metabolite(s) of Fosaprepitant. Fosaprepitant may decrease the serum concentration of PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Galantamine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Galantamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: May enhance the adverse/toxic effect of PARoxetine. Specifically, blood glucose elevations may occur with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: PARoxetine may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F206589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Peak concentration is increased, but bioavailability is not significantly altered by food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, tryptophan, SAMe, kava kava.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F206578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Studies in pregnant women have demonstrated a risk to the fetus. Paroxetine crosses the placenta. An increased risk of teratogenic effects, including cardiovascular defects, may be associated with maternal use of paroxetine or other SSRIs; however, available information is conflicting. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of paroxetine may be altered. The maternal CYP2D6 genotype also influences paroxetine plasma concentrations during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The manufacturer suggests discontinuing paroxetine or switching to another antidepressant unless the benefits of therapy justify continuing treatment during pregnancy; consider other treatment options for women who are planning to become pregnant. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. The ACOG also recommends that therapy with paroxetine be avoided during pregnancy if possible and that fetuses exposed in early pregnancy be assessed with a fetal echocardiography. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. The use of paroxetine is not recommended as first line therapy during pregnancy. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F206606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4034699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paroxetine is excreted in breast milk and concentrations in the hindmilk are higher than in foremilk. Paroxetine has not been detected in the serum of nursing infants. Adverse reactions have been reported in nursing infants exposed to some SSRIs. The manufacturer recommends that caution be exercised when administering paroxetine to nursing women. Maternal use of an SSRI during pregnancy may cause delayed milk secretion. The American Academy of Breastfeeding Medicine suggests that paroxetine may be considered for the treatment of postpartum depression in appropriately selected women who are nursing. Mothers should be monitored for changes in symptoms and infants should be monitored for growth. The long-term effects on development and behavior have not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F206579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F206577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Paxil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (250 mL): $254.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (PARoxetine HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (30): $108.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $113.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5 mg (30): $116.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Paxil CR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (30): $150.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $157.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5 mg (30): $162.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (PARoxetine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $78.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $81.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $84.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $89.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Paxil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $146.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $152.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $157.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $166.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pexeva Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $235.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $244.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $253.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $263.33",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F206564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mental status for depression, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks; signs/symptoms of serotonin syndrome; akathisia",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F206580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A-Xat CR (KP);",
"     </li>",
"     <li>",
"      Aropax (LU, MX);",
"     </li>",
"     <li>",
"      Aropax 20 (AR, AU, BE, BR, NZ, PY, UY, ZA);",
"     </li>",
"     <li>",
"      Aroxat (CN);",
"     </li>",
"     <li>",
"      Deroxat (CH, FR);",
"     </li>",
"     <li>",
"      Divarius (FR);",
"     </li>",
"     <li>",
"      Extine (AU);",
"     </li>",
"     <li>",
"      Loxamine (NZ);",
"     </li>",
"     <li>",
"      PARI CR (IN);",
"     </li>",
"     <li>",
"      Parotin (HK);",
"     </li>",
"     <li>",
"      Paroxil CR (KP);",
"     </li>",
"     <li>",
"      Paxan (CO);",
"     </li>",
"     <li>",
"      Paxetil (KP);",
"     </li>",
"     <li>",
"      Paxil (BB, BM, BS, BZ, CR, DO, EC, GT, GY, HN, JM, MX, NI, PA, PR, RU, SR, SV, TR, TT, VE);",
"     </li>",
"     <li>",
"      Paxil CR (BB, BM, BS, BZ, CR, DO, EC, GT, GY, HN, JM, KP, NI, PA, PR, SR, SV, TT);",
"     </li>",
"     <li>",
"      Paxtine (AU);",
"     </li>",
"     <li>",
"      Paxxet (IL);",
"     </li>",
"     <li>",
"      Seroxat (AE, AT, BD, BF, BH, BJ, CI, CL, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, HK, HU, ID, IE, IL, IQ, IR, IT, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, OM, PE, PH, PK, PL, PT, QA, SA, SC, SD, SE, SG, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Seroxat CR (HK, SG, TH);",
"     </li>",
"     <li>",
"      Setine (TW);",
"     </li>",
"     <li>",
"      Tagonis (DE);",
"     </li>",
"     <li>",
"      XET (TW);",
"     </li>",
"     <li>",
"      Xetanor (BG);",
"     </li>",
"     <li>",
"      Xetine-P (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F206554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paroxetine is a selective serotonin reuptake inhibitor, chemically unrelated to tricyclic, tetracyclic, or other antidepressants; presumably, the inhibition of serotonin reuptake from brain synapse stimulated serotonin activity in the brain",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F206573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Depression: The onset of action is within a week; however, individual response varies greatly and full response may not be seen until 8-12 weeks after initiation of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Completely absorbed following oral administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 8.7 L/kg (3-28 L/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP2D6 enzymes; primary metabolites are formed via oxidation and methylation of parent drug, with subsequent glucuronide/sulfate conjugation; nonlinear pharmacokinetics (via 2D6 saturation) may be seen with higher doses and longer duration of therapy. Metabolites exhibit ~2% potency of parent compound. C",
"     <sub>",
"      min",
"     </sub>",
"     concentrations are 70% to 80% greater in the elderly compared to nonelderly patients; clearance is also decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 21 hours (3-65 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Immediate release: 5.2-8.1 hours; controlled release: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (64%, 2% as unchanged drug); feces (36% primarily via bile, &lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adler LA and Angrist BM, &ldquo;Paroxetine and Akathisia,&rdquo;",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 1995, 37(5):336-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/7748986/pubmed\" id=\"7748986\" target=\"_blank\">",
"        7748986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ahmad S, &ldquo;Paroxetine-Induced Priapism,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1995, 155(6):645.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/7887764/pubmed\" id=\"7887764\" target=\"_blank\">",
"        7887764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bandelow B, Zohar J, Hollander E, et al, &ldquo;World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders -- First Revision,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2008, 9(4): 248-312. Available at file://www.wfsbp.org/fileadmin/pdf/guides/Guidelines_Anxiety_revision.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/18949648/pubmed\" id=\"18949648\" target=\"_blank\">",
"        18949648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo; Available at  file://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=AcuteStressDisorder-PTSD_GuidelineWatch",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bloch M, Stager SV, Braun AR, et al, &ldquo;Severe Psychiatric Symptoms Associated With Paroxetine Withdrawal,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 346(8966):57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/7603169/pubmed\" id=\"7603169\" target=\"_blank\">",
"        7603169",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352:1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer WF and Blumhardt CL, &ldquo;The Safety Profile of Paroxetine,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1992, 53(Suppl):61-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/1531828/pubmed\" id=\"1531828\" target=\"_blank\">",
"        1531828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/16467545/pubmed\" id=\"16467545\" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dechant KL and Clissold SP, &ldquo;Paroxetine: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Depressive Illness,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1991, 41(2):225-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/1709852/pubmed\" id=\"1709852\" target=\"_blank\">",
"        1709852",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diler RS and Avci A, &ldquo;Selective Serotonin Reuptake Inhibitor Discontinuation Syndrome in Children: Six Case Reports,&rdquo;",
"      <i>",
"       Current Therapeutic Research",
"      </i>",
"      , 2002, 63(3):188-97.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkley EJ, Isbister GK, Sibbritt D, et al, &ldquo;The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,&rdquo;",
"      <i>",
"       QJM",
"      </i>",
"      , 2003, 96(9):635-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/12925718/pubmed\" id=\"12925718\" target=\"_blank\">",
"        12925718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fava M, Judge R, Hoog SL, et al, &ldquo;Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder: Changes in Weight With Long-Term Treatment,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2000, 61(11):863-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/11105740/pubmed\" id=\"11105740\" target=\"_blank\">",
"        11105740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller DA, Wagner KD, Emslie G, et al, &ldquo;Paroxetine Treatment in Children and Adolescents With Obsessive-Compulsive Disorder: A Radomized, Multicenter, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2004, 43(11):1387-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/15502598/pubmed\" id=\"15502598\" target=\"_blank\">",
"        15502598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grimsley SR and Jann MW, &ldquo;Paroxetine, Sertraline, and Fluvoxamine: New Selective Serotonin Reuptake Inhibitors,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1992, 11(11):930-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/1464219/pubmed\" id=\"1464219\" target=\"_blank\">",
"        1464219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hebenstreit GF, Fellerer K, Zochling R, et al, &ldquo;A Pharmacokinetic Dose Titration Study in Adult and Elderly Depressed Patients,&rdquo;",
"      <i>",
"       Acta Psychiatr Scand Suppl",
"      </i>",
"      , 1989, 350:81-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/2530795/pubmed\" id=\"2530795\" target=\"_blank\">",
"        2530795",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horrigan JP and Barnhill LJ, &ldquo;Paroxetine-Pimozide Drug Interactions,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1994, 33(7):1060-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/7961347/pubmed\" id=\"7961347\" target=\"_blank\">",
"        7961347",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G, et al, &ldquo;Parkinsonism Exacerbated by Paroxetine,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1994, 44(12):2406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/7991139/pubmed\" id=\"7991139\" target=\"_blank\">",
"        7991139",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keller MB, Ryan ND, Strober M, et al, &ldquo;Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2001, 40(7):762-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/11437014/pubmed\" id=\"11437014\" target=\"_blank\">",
"        11437014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar VS, Sharma VL, Tiwari P, et al, \"The Spermicidal and Antitrichomonas Activities of SSRI Antidepressants,\"",
"      <i>",
"       Bioorg Med Chem Lett",
"      </i>",
"      ,  2006, 16(9):2509-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/16464584/pubmed\" id=\"16464584\" target=\"_blank\">",
"        16464584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lundmark J, Scheel Thomsen I, Fjord-Larsen T, et al, &ldquo;Paroxetine: Pharmacokinetic and Antidepressant Effect in the Elderly,&rdquo;",
"      <i>",
"       Acta Psychiatr Scand Suppl",
"      </i>",
"      , 1989, 350:76-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/2530794/pubmed\" id=\"2530794\" target=\"_blank\">",
"        2530794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malek-Ahmadi P and Allen SA, &ldquo;Paroxetine-Molindone Interaction,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1995, 56(2):82-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/7852260/pubmed\" id=\"7852260\" target=\"_blank\">",
"        7852260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mancini C, Van Ameringen M, Oakman JM, et al, &ldquo;Serotonergic Agents in the Treatment of Social Phobia in Children and Adolescents: A Case Series,&rdquo;",
"      <i>",
"       Depress Anxiety",
"      </i>",
"      , 1999, 10(1):33-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/10499188/pubmed\" id=\"10499188\" target=\"_blank\">",
"        10499188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McKenzie LJ and Risch SC, &ldquo;Fibrocystic Breast Disease Following Treatment With Selective Serotonin Reuptake Inhibitors,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(3):471.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/7864280/pubmed\" id=\"7864280\" target=\"_blank\">",
"        7864280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nemeroff CB, &ldquo;The Clinical Pharmacology and Use of Paroxetine, A New Selective Serotonin Reuptake Inhibitor,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1994, 14(2):127-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/8197030/pubmed\" id=\"8197030\" target=\"_blank\">",
"        8197030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Norden MJ, &ldquo;Buspirone Treatment of Sexual Dysfunction Associated With Selective Serotonin Re-Uptake Inhibitors,&rdquo;",
"      <i>",
"       Depression",
"      </i>",
"      , 1994, 2:109-12.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reeves RR and Bullen JA, &ldquo;Serotonin Syndrome Produced by Paroxetine and Low-Dose Trazodone,&rdquo;",
"      <i>",
"       Psychosomatics",
"      </i>",
"      , 1995, 36(2):159-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/7724720/pubmed\" id=\"7724720\" target=\"_blank\">",
"        7724720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rey-Sanchez F and Guitierrez-Cassares JR, &ldquo;Paroxetine in Children With Major Depressive Disorder: An Open Trial,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1997, 36(10):1443-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/9334558/pubmed\" id=\"9334558\" target=\"_blank\">",
"        9334558",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roose SP, Glassman AH, Attia E, et al, &ldquo;Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1994, 151(12):1735-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/7977878/pubmed\" id=\"7977878\" target=\"_blank\">",
"        7977878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roose SP, Laghrissi-Thode F, Kennedy JS, et al, &ldquo;Comparison of Paroxetine and Nortriptyline in Depressed Patients With Ischemic Heart Disease,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(4):287-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/9450712/pubmed\" id=\"9450712\" target=\"_blank\">",
"        9450712",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenberg DR, Stewart CM, Fitzgerald KD, et al, &ldquo;Paroxetine Open-Label Treatment of Pediatric Outpatients With Obsessive-Compulsive Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1999, 38(9):1180-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/10504818/pubmed\" id=\"10504818\" target=\"_blank\">",
"        10504818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schone W and Ludwig M, &ldquo;A Double-Blind Study of Paroxetine Compared With Fluoxetine in Geriatric Patients With Major Depression,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1993, 13(6 Suppl 2):34-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharp SC and Hellings JA, &ldquo;Efficacy and Safety of SSRI in the Treatment of Depression in Children and Adolescents: Practitioner Review,&rdquo;",
"      <i>",
"       Clin Drug Inv",
"      </i>",
"      , 2006, 26(5):247-55.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skop BP, Finkelstein JA, Mareth TR, et al, &ldquo;The Serotonin Syndrome Associated With Paroxetine, an Over-the-Counter Cold Remedy, and Vascular Disease,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1994, 12(6):642-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/7945606/pubmed\" id=\"7945606\" target=\"_blank\">",
"        7945606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snead RW, Boon F, and Presberg J, &ldquo;Paroxetine for Self-Injurious Behavior,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1994, 33(6):909-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/8083152/pubmed\" id=\"8083152\" target=\"_blank\">",
"        8083152",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spina E, Avenoso A, Facciola G, et al, &ldquo;Relationship Between Plasma Risperidone and 9-hydroxyrisperidone Concentrations and Clinical Response in Patients With Schizophrenia,&rdquo;",
"      <i>",
"       Psychopharmacology (Berl)",
"      </i>",
"      , 2001, 153(2):238-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stearns V, Beebe KL, Iyengar M, et al, &ldquo;Paroxetine Controlled Release in the Treatment of Menopausal Hot Flashes: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(21):2827-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/12783913/pubmed\" id=\"12783913\" target=\"_blank\">",
"        12783913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, &ldquo;Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(9):1290-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stiskal JA, Kulin N, Koren G, et al, &ldquo;Neonatal Paroxetine Withdrawal Syndrome,&rdquo;",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 2001, 84(2):F134-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/11207233/pubmed\" id=\"11207233\" target=\"_blank\">",
"        11207233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tanrikut C, Feldman AS, Altemus M, et al, \"Adverse Effect of Paroxetine on Sperm,",
"      <i>",
"       Fertil Steril",
"      </i>",
"      , 2010, 94(3):1021-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/19515367/pubmed\" id=\"19515367\" target=\"_blank\">",
"        19515367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thibaut F, De La Barra F, Gordon H, et al, &ldquo;The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Paraphilias,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2010, 11(4):604-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/20459370/pubmed\" id=\"20459370\" target=\"_blank\">",
"        20459370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, Berard R, Stein MB, et al, &ldquo;A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Paroxetine in Children and Adolescents With Social Anxiety Disorder,&rdquo;",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 2004, 61(11):1153-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/15520363/pubmed\" id=\"15520363\" target=\"_blank\">",
"        15520363",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/50/15146/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9743 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15146=[""].join("\n");
var outline_f14_50_15146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709196\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206594\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206595\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206637\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206599\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206618\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206600\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206601\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206602\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206567\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206551\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874764\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206571\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206570\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206633\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206646\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206635\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206574\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206555\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206630\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206560\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206589\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206562\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206578\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206606\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4034699\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206579\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206577\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206564\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206580\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206554\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206573\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9743\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9743|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/12/17606?source=related_link\">",
"      Paroxetine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18361?source=related_link\">",
"      Paroxetine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_50_15147="Complications of vagal maneuvers";
var content_f14_50_15147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential complications of selected vagal maneuvers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vagal maneuver",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential complication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carotid sinus massage",
"       </td>",
"       <td>",
"        Decreased cerebral perfusion, cerebral embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ice-water immersion",
"       </td>",
"       <td>",
"        Aspiration, drowning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eyeball compression",
"       </td>",
"       <td>",
"        Ocular injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valsalva maneuver",
"       </td>",
"       <td>",
"        Rupture of the round window of the ear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digital rectal exam",
"       </td>",
"       <td>",
"        Bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gagging, tongue pulling",
"       </td>",
"       <td>",
"        Vomiting, aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MAST garment",
"       </td>",
"       <td>",
"        Compartment syndrome, myoglobinuria",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter J Zimetbaum, MD and Daniel Frisch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15147=[""].join("\n");
var outline_f14_50_15147=null;
var title_f14_50_15148="MSI testing Bethesda";
var content_f14_50_15148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for the process of molecular evaluation of patients identified as being at risk, based on meeting the Bethesda guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Process of molecular evaluation:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. The optimal approach to evaluation is microsatellite instability (MSI) or immunohistochemical (IHC) analysis* of tumors, followed by germline MSH2/MLH1 testing in patients with MSI-H tumors or tumors with a loss of expression of one of the mismatch repair genes&bull;.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. After the mutation is identified, at-risk relatives should be referred for genetic counseling and tested if they wish.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. An alternative approach, if tissue testing is not feasible, is to proceed directly to germline analysis of the MSH2/MLH1 genes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. If no mismatch repair gene mutation is found in a proband with an MSI-H tumor and/or clinical history of hereditary nonpolyposis colorectal cancer (HNPCC), the genetic test result is non-informative. The patients and the at-risk individuals (ie, relatives) should be counseled as if HNPCC was confirmed and high-risk surveillance should be undertaken.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. There is need to assure patients of confidentiality to allay fears related to discrimination based on genetic status.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MSI-H: microsatellite instability-high in tumors refers to changes in two or more of the five National Cancer Institute (NCI)-recommended panels of microsatellite markers. MSI-L: microsatellite instability-low in tumors refers to changes in only one of the five NCI-recommended panels of microsatellite markers.",
"     <br>",
"      * Standard mutation detection techniques include single-strand conformational polymorphism, denaturing gradient gel-electrophoresis analysis, and DNA sequencing. Alternative mutation detection techniques include monoallelic expression analysis, Southern analysis, and quantitative polymerase chain reaction; these methods may detect certain mutations such as large genomic rearrangements that may be missed by more conventional mutation detection methods.",
"      <br>",
"       &bull; For families with a strong suspicion of HNPCC, germline testing should be considered, even when the MSI/IHC results indicate MSI-L, microsatellite stable, or normal expression. The likelihood of finding a germline mutation in the MLH1/MSH2 genes of patients with colorectal cancer tumors that are not MSI-H is expected to be low; however, this likelihood has not been thoroughly studied.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Umar, A, et al. J Natl Cancer Inst 2004; 96:261. Copyright &copy; 2004 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15148=[""].join("\n");
var outline_f14_50_15148=null;
var title_f14_50_15149="Clues to the etiology of septic arthritis in children";
var content_f14_50_15149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features associated with bacterial pathogens that cause arthritis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Gram-positive bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"       <td>",
"        All ages; may cause polyarticular infection; MRSA may be associated with venous thromboembolism and pulmonary disease; possible associated skin or soft tissue infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coagulase-negative staphylococci",
"       </td>",
"       <td>",
"        Most common cause of bacterial arthritis associated with prosthetic joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Group A streptococcus (",
"        <em>",
"         S. pyogenes",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        Concurrent varicella zoster virus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"        (pneumococcus)",
"       </td>",
"       <td>",
"        Children younger than two years of age; children older than two years of age with underlying medical condition (eg, sickle cell disease, immunodeficiency, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Group B streptococcus (",
"        <em>",
"         Streptococcus agalactiae",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        Infants younger than three months of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Nocardia asteroides",
"        </em>",
"       </td>",
"       <td>",
"        Chronic monoarticular arthritis with a granulomatous reaction",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Gram-negative bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Kingella kingae",
"        </em>",
"       </td>",
"       <td>",
"        Children younger than 36 months, indolent onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"        type b (Hib)",
"       </td>",
"       <td>",
"        Incompletely immunized children in areas with low Hib immunization rates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Neisseria gonorrhoeae",
"        </em>",
"       </td>",
"       <td>",
"        Newborns; usually affects joints below the hip; may cause polyarticular infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sexually active adolescents; usually occurs as part of disseminated infection with fever and rash; in girls may precede onset of menses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Neisseria meningitidis",
"        </em>",
"       </td>",
"       <td>",
"        May cause polyarticular infection; associated rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Salmonella",
"        </em>",
"        species",
"       </td>",
"       <td>",
"        Children with sickle cell disease or related hemoglobinopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-salmonella gram-negative bacilli",
"       </td>",
"       <td>",
"        Newborns; instrumentation of the gastrointestinal or urinary tract; immunocompromised host",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Pseudomonas aeruginosa",
"        </em>",
"       </td>",
"       <td>",
"        Puncture wounds; injectable drug use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Streptococcus moniliformis",
"        </em>",
"        (rat bite fever)",
"       </td>",
"       <td>",
"        Rat bite; macular rash at time of presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Borrelia burgdorferi",
"        </em>",
"        (Lyme disease)",
"       </td>",
"       <td>",
"        Tick bite; history of erythema migrans rash; travel to or living in an endemic area; intermittent inflammatory arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Brucella",
"        </em>",
"       </td>",
"       <td>",
"        Travel to or living in an endemic area; ingestion of unpasteurized dairy products; chronic monoarticular arthritis with a granulomatous reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycobacteria (tuberculosis and atypical species)",
"       </td>",
"       <td>",
"        Chronic monoarticular arthritis with a granulomatous reaction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRSA: methicillin-resistant",
"     <em>",
"      S. aureus",
"     </em>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Krogstad P. Septic arthitis. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.742.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15149=[""].join("\n");
var outline_f14_50_15149=null;
var title_f14_50_15150="LH pulses and sleep";
var content_f14_50_15150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Episodic LH secretion during the follicular phase",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 305px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patterns of episodic LH secretion during early (EFP), middle (MFP), and late (LFP) phases of the menstrual cycle. Day 0 is the day of the midcycle LH surge. There is a unique suppression of LH secretion during sleep in the EFP.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Filicori, M, Santoro, N, Merriam, GR, Crowley, WF Jr, J Clin Endocrinol Metab 1986; 62:1136.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15150=[""].join("\n");
var outline_f14_50_15150=null;
var title_f14_50_15151="Sesamoid under 5th mcp oblique";
var content_f14_50_15151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small sesamoid underlying the fifth metatarsophalangeal joint (white arrow)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This oblique view also shows the medial and lateral sesamoids below the metatarsophalangeal joint of the great toe (black arrow), and a nondisplaced, transverse fracture of the proximal phalanx of the little toe (grey arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_50_15151=[""].join("\n");
var outline_f14_50_15151=null;
